{"text_format":"3","workbook":"xlsx","n_sheets":56,"sheets":["COVER","CONDENSED CONSOLIDATED BALANCE ","CONDENSED CONSOLIDATED STATEMEN","CONDENSED CONSOLIDATED STATEM_2","CONDENSED CONSOLIDATED STATEM_3","SUMMARY OF SIGNIFICANT ACCOUNTI","NEW ACCOUNTING PRONOUNCEMENTS","BUSINESS COMBINATIONS","ACCOUNTS RECEIVABLE, NET","DEBT AND FINANCING ARRANGEMENTS","COMMITMENTS AND CONTINGENCIES","FINANCIAL INSTRUMENTS","FAIR VALUE MEASUREMENTS","OTHER COMPREHENSIVE INCOME","EMPLOYEE STOCK PLANS","EARNINGS PER SHARE","SEGMENT DISCLOSURES","SUBSEQUENT EVENTS","Pay vs Performance Disclosure","Insider Trading Arrangements","SUMMARY OF SIGNIFICANT ACCOUN_2","BUSINESS COMBINATIONS (Tables)","ACCOUNTS RECEIVABLE, NET (Table","DEBT AND FINANCING ARRANGEMEN_2","FINANCIAL INSTRUMENTS (Tables)","FAIR VALUE MEASUREMENTS (Tables","OTHER COMPREHENSIVE INCOME (Tab","EMPLOYEE STOCK PLANS (Tables)","EARNINGS PER SHARE (Tables)","SEGMENT DISCLOSURES (Tables)","SUMMARY OF SIGNIFICANT ACCOUN_3","BUSINESS COMBINATIONS - Additio","BUSINESS COMBINATIONS - Summary","ACCOUNTS RECEIVABLE, NET - Summ","ACCOUNTS RECEIVABLE, NET - Su_2","DEBT AND FINANCING ARRANGEMEN_3","DEBT AND FINANCING ARRANGEMEN_4","DEBT AND FINANCING ARRANGEMEN_5","COMMITMENTS AND CONTINGENCIES -","COMMITMENTS AND CONTINGENCIES_2","FINANCIAL INSTRUMENTS - Additio","FINANCIAL INSTRUMENTS - Summary","FINANCIAL INSTRUMENTS - Summa_2","FINANCIAL INSTRUMENTS - Summa_3","FAIR VALUE MEASUREMENTS - Summa","FAIR VALUE MEASUREMENTS - Sum_2","FAIR VALUE MEASUREMENTS - Sum_3","OTHER COMPREHENSIVE INCOME (Det","EMPLOYEE STOCK PLANS - Addition","EMPLOYEE STOCK PLANS - Summary ","EMPLOYEE STOCK PLANS - Summar_2","EMPLOYEE STOCK PLANS - Summar_3","EARNINGS PER SHARE (Details)","SEGMENT DISCLOSURES - Additiona","SEGMENT DISCLOSURES - Summary o","SUBSEQUENT EVENTS (Details)"],"read":"whole","date_system":"1900"}

{"sheet":"COVER","index":0,"n_rows":33,"n_cols":3,"rows_kept":33,"merged":[[0,0,1,0]]}
["COVER - shares","3 Months Ended"]
[null,"Mar. 31, 2025","Apr. 21, 2025"]
["Cover [Abstract]"," "," "]
["Document Type","10-Q"," "]
["Document Quarterly Report","true"," "]
["Document Period End Date","Mar. 31,  2025"," "]
["Document Transition Report","false"," "]
["Entity File Number","1-32961"," "]
["Entity Registrant Name","CBIZ, Inc."," "]
["Entity Incorporation, State or Country Code","DE"," "]
["Entity Tax Identification Number","22-2769024"," "]
["Entity Address, Address Line One","5959 Rockside Woods"," "]
["Entity Address, Address Line Two","N. Suite 600"," "]
["Entity Address, City or Town","Independence"," "]
["Entity Address, State or Province","OH"," "]
["Entity Address, Postal Zip Code","44131"," "]
["City Area Code","216"," "]
["Local Phone Number","447-9000"," "]
["Title of 12(b) Security","Common Stock, $0.01 Par Value"," "]
["Trading Symbol","CBZ"," "]
["Security Exchange Name","NYSE"," "]
["Entity Current Reporting Status","Yes"," "]
["Entity Interactive Data Current","Yes"," "]
["Entity Filer Category","Large Accelerated Filer"," "]
["Entity Small Business","false"," "]
["Entity Emerging Growth Company","false"," "]
["Entity Shell Company","false"," "]
["Entity Common Stock, Shares Outstanding"," ",{"v":54395610,"d":"54,395,610 "}]
["Amendment Flag","false"," "]
["Document Fiscal Year Focus","2025"," "]
["Document Fiscal Period Focus","Q1"," "]
["Entity Central Index Key","0000944148"," "]
["Current Fiscal Year End Date","--12-31"," "]

{"sheet":"CONDENSED CONSOLIDATED BALANCE ","index":1,"n_rows":48,"n_cols":4,"rows_kept":48,"merged":[[0,0,0,1],[46,0,46,2],[47,0,47,2]]}
["CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands",null,"Mar. 31, 2025","Dec. 31, 2024"]
["Current assets:",null," "," "]
["Cash and cash equivalents",null,{"v":8850,"d":"$ 8,850"},{"v":13826,"d":"$ 13,826"}]
["Restricted cash",null,{"v":40777,"d":"40,777 "},{"v":38661,"d":"38,661 "}]
["Accounts receivable, net",null,{"v":735426,"d":"735,426 "},{"v":534858,"d":"534,858 "}]
["Other current assets",null,{"v":76847,"d":"76,847 "},{"v":72528,"d":"72,528 "}]
["Current assets before funds held for clients",null,{"v":861900,"d":"861,900 "},{"v":659873,"d":"659,873 "}]
["Funds held for clients",null,{"v":140932,"d":"140,932 "},{"v":175853,"d":"175,853 "}]
["Total current assets",null,{"v":1002832,"d":"1,002,832 "},{"v":835726,"d":"835,726 "}]
["Non-current assets:",null," "," "]
["Property and equipment, net",null,{"v":92092,"d":"92,092 "},{"v":88163,"d":"88,163 "}]
["Goodwill and other intangible assets, net",null,{"v":2906525,"d":"2,906,525 "},{"v":2945470,"d":"2,945,470 "}]
["Assets of deferred compensation plan",null,{"v":162066,"d":"162,066 "},{"v":167170,"d":"167,170 "}]
["Right-of-use assets, net",null,{"v":382051,"d":"382,051 "},{"v":393512,"d":"393,512 "}]
["Other non-current assets",null,{"v":39932,"d":"39,932 "},{"v":40842,"d":"40,842 "}]
["Total non-current assets",null,{"v":3582666,"d":"3,582,666 "},{"v":3635157,"d":"3,635,157 "}]
["Total assets",null,{"v":4585498,"d":"4,585,498 "},{"v":4470883,"d":"4,470,883 "}]
["Current liabilities:",null," "," "]
["Accounts payable",null,{"v":102646,"d":"102,646 "},{"v":90646,"d":"90,646 "}]
["Income taxes payable",null,{"v":42388,"d":"42,388 "},{"v":0,"d":"0 "}]
["Accrued personnel costs",null,{"v":87874,"d":"87,874 "},{"v":172759,"d":"172,759 "}]
["Contingent purchase price liabilities",null,{"v":46731,"d":"46,731 "},{"v":61164,"d":"61,164 "}]
["Operating lease liabilities",null,{"v":61673,"d":"61,673 "},{"v":60549,"d":"60,549 "}]
["Short-term debt","[1]",{"v":66226,"d":"66,226 "},{"v":66177,"d":"66,177 "}]
["Other current liabilities",null,{"v":111658,"d":"111,658 "},{"v":78579,"d":"78,579 "}]
["Current liabilities before client fund obligations",null,{"v":519196,"d":"519,196 "},{"v":529874,"d":"529,874 "}]
["Client fund obligations",null,{"v":140867,"d":"140,867 "},{"v":175928,"d":"175,928 "}]
["Total current liabilities",null,{"v":660063,"d":"660,063 "},{"v":705802,"d":"705,802 "}]
["Non-current liabilities:",null," "," "]
["Long-term debt","[1]",{"v":1462504,"d":"1,462,504 "},{"v":1333755,"d":"1,333,755 "}]
["Income taxes payable",null,{"v":2538,"d":"2,538 "},{"v":2193,"d":"2,193 "}]
["Deferred income taxes, net",null,{"v":1022,"d":"1,022 "},{"v":10880,"d":"10,880 "}]
["Deferred compensation plan obligations",null,{"v":162066,"d":"162,066 "},{"v":167170,"d":"167,170 "}]
["Contingent purchase price liabilities",null,{"v":19232,"d":"19,232 "},{"v":35803,"d":"35,803 "}]
["Lease liabilities",null,{"v":360140,"d":"360,140 "},{"v":372586,"d":"372,586 "}]
["Other non-current liabilities",null,{"v":3232,"d":"3,232 "},{"v":62711,"d":"62,711 "}]
["Total non-current liabilities",null,{"v":2010734,"d":"2,010,734 "},{"v":1985098,"d":"1,985,098 "}]
["Total liabilities",null,{"v":2670797,"d":"2,670,797 "},{"v":2690900,"d":"2,690,900 "}]
["STOCKHOLDERS' EQUITY",null," "," "]
["Common stock",null,{"v":1420,"d":"1,420 "},{"v":1380,"d":"1,380 "}]
["Additional paid in capital",null,{"v":1812729,"d":"1,812,729 "},{"v":1791863,"d":"1,791,863 "}]
["Retained earnings",null,{"v":1018895,"d":"1,018,895 "},{"v":896122,"d":"896,122 "}]
["Treasury stock",null,{"v":-918327,"d":"(918,327)"},{"v":-910601,"d":"(910,601)"}]
["Accumulated other comprehensive (loss) income",null,{"v":-16,"d":"(16)"},{"v":1219,"d":"1,219 "}]
["Total stockholders’ equity",null,{"v":1914701,"d":"1,914,701 "},{"v":1779983,"d":"1,779,983 "}]
["Total liabilities and stockholders’ equity",null,{"v":4585498,"d":"$ 4,585,498"},{"v":4470883,"d":"$ 4,470,883"}]
[]
["[1] Reflects the net debt for the Term Loan and Revolver with the associated debt issuance costs in short-term and long-term liabilities. See Note 5. Debt and Financing Arrangements for further discussion of the short-term and long-term debt."]

{"sheet":"CONDENSED CONSOLIDATED STATEMEN","index":2,"n_rows":24,"n_cols":3,"rows_kept":24,"merged":[[0,0,1,0],[0,1,0,2]]}
["CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Statement of Comprehensive Income [Abstract]"," "," "]
["Revenue",{"v":838014,"d":"$ 838,014"},{"v":494297,"d":"$ 494,297"}]
["Operating expenses",{"v":609912,"d":"609,912 "},{"v":376485,"d":"376,485 "}]
["Gross margin",{"v":228102,"d":"228,102 "},{"v":117812,"d":"117,812 "}]
["Corporate general and administrative expenses",{"v":28070,"d":"28,070 "},{"v":18711,"d":"18,711 "}]
["Operating income",{"v":200032,"d":"200,032 "},{"v":99101,"d":"99,101 "}]
["Other (expense) income:"," "," "]
["Interest expense",{"v":-25156,"d":"(25,156)"},{"v":-4511,"d":"(4,511)"}]
["Other (expense) income, net",{"v":-1966,"d":"(1,966)"},{"v":9424,"d":"9,424 "}]
["Total other (expense) income, net",{"v":-27122,"d":"(27,122)"},{"v":4913,"d":"4,913 "}]
["Income before income tax expense",{"v":172910,"d":"172,910 "},{"v":104014,"d":"104,014 "}]
["Income tax expense",{"v":50137,"d":"50,137 "},{"v":27130,"d":"27,130 "}]
["Net Income",{"v":122773,"d":"$ 122,773"},{"v":76884,"d":"$ 76,884"}]
["Earnings per share:"," "," "]
["Basic (in dollars per share)",{"v":1.92,"d":"$ 1.92"},{"v":1.54,"d":"$ 1.54"}]
["Diluted (in dollars per share)",{"v":1.91,"d":"$ 1.91"},{"v":1.53,"d":"$ 1.53"}]
["Basic weighted average shares outstanding (in shares)",{"v":63843,"d":"63,843 "},{"v":50045,"d":"50,045 "}]
["Diluted weighted average shares outstanding (in shares)",{"v":64142,"d":"64,142 "},{"v":50221,"d":"50,221 "}]
["Comprehensive income:"," "," "]
["Net income",{"v":122773,"d":"$ 122,773"},{"v":76884,"d":"$ 76,884"}]
["Other comprehensive (loss) income, net of tax",{"v":-1235,"d":"(1,235)"},{"v":1018,"d":"1,018 "}]
["Comprehensive income",{"v":121538,"d":"$ 121,538"},{"v":77902,"d":"$ 77,902"}]

{"sheet":"CONDENSED CONSOLIDATED STATEM_2","index":3,"n_rows":33,"n_cols":13,"rows_kept":33}
["CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands","Total","Restricted stock units and awards","Performance share units","Common Stock","Common Stock Restricted stock units and awards","Common Stock Performance share units","Treasury Shares","Additional Paid-In Capital","Additional Paid-In Capital Restricted stock units and awards","Additional Paid-In Capital Performance share units","Retained Earnings","Accumulated Other Comprehensive Income (Loss)"]
["Common stock, beginning balance (in shares) at Dec. 31, 2023"," "," "," ",{"v":137387,"d":"137,387 "}," "," "," "," "," "," "," "," "]
["Treasury stock, beginning balance (in shares) at Dec. 31, 2023"," "," "," "," "," "," ",{"v":87573,"d":"87,573 "}," "," "," "," "," "]
["Beginning balance at Dec. 31, 2023",{"v":791618,"d":"$ 791,618"}," "," ",{"v":1374,"d":"$ 1,374"}," "," ",{"v":-899093,"d":"$ (899,093)"},{"v":832475,"d":"$ 832,475"}," "," ",{"v":855084,"d":"$ 855,084"},{"v":1778,"d":"$ 1,778"}]
["Increase (Decrease) in Stockholders' Equity [Roll Forward]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Net income",{"v":76884,"d":"76,884 "}," "," "," "," "," "," "," "," "," ",{"v":76884,"d":"76,884 "}," "]
["Other comprehensive income (loss), net of tax",{"v":1018,"d":"1,018 "}," "," "," "," "," "," "," "," "," "," ",{"v":1018,"d":"1,018 "}]
["Indirect repurchase of shares for minimum tax withholding (in shares)"," "," "," "," "," "," ",{"v":170,"d":"170 "}," "," "," "," "," "]
["Indirect repurchase of shares for minimum tax withholding",{"v":-11229,"d":"(11,229)"}," "," "," "," "," ",{"v":-11229,"d":"$ (11,229)"}," "," "," "," "," "]
["Restricted stock units and awards and performance share units (in shares)"," "," "," "," ",{"v":102,"d":"102 "},{"v":273,"d":"273 "}," "," "," "," "," "," "]
["Restricted stock units and awards and performance share units"," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}," ",{"v":1,"d":"$ 1"},{"v":3,"d":"$ 3"}," "," ",{"v":-1,"d":"$ (1)"},{"v":-3,"d":"$ (3)"}," "," "]
["Stock-based compensation",{"v":2638,"d":"2,638 "}," "," "," "," "," "," ",{"v":2638,"d":"2,638 "}," "," "," "," "]
["Business acquisitions (in shares)"," "," "," ",{"v":93,"d":"93 "}," "," "," "," "," "," "," "," "]
["Business acquisitions",{"v":6160,"d":"6,160 "}," "," ",{"v":1,"d":"$ 1"}," "," "," ",{"v":6159,"d":"6,159 "}," "," "," "," "]
["Common stock, ending balance (in shares) at Mar. 31, 2024"," "," "," ",{"v":137855,"d":"137,855 "}," "," "," "," "," "," "," "," "]
["Treasury stock, ending balance (in shares) at Mar. 31, 2024"," "," "," "," "," "," ",{"v":87743,"d":"87,743 "}," "," "," "," "," "]
["Ending balance at Mar. 31, 2024",{"v":867089,"d":"867,089 "}," "," ",{"v":1379,"d":"$ 1,379"}," "," ",{"v":-910322,"d":"$ (910,322)"},{"v":841268,"d":"841,268 "}," "," ",{"v":931968,"d":"931,968 "},{"v":2796,"d":"2,796 "}]
["Common stock, beginning balance (in shares) at Dec. 31, 2024"," "," "," ",{"v":137945,"d":"137,945 "}," "," "," "," "," "," "," "," "]
["Treasury stock, beginning balance (in shares) at Dec. 31, 2024"," "," "," "," "," "," ",{"v":87747,"d":"87,747 "}," "," "," "," "," "]
["Beginning balance at Dec. 31, 2024",{"v":1779983,"d":"1,779,983 "}," "," ",{"v":1380,"d":"$ 1,380"}," "," ",{"v":-910601,"d":"$ (910,601)"},{"v":1791863,"d":"1,791,863 "}," "," ",{"v":896122,"d":"896,122 "},{"v":1219,"d":"1,219 "}]
["Increase (Decrease) in Stockholders' Equity [Roll Forward]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Net income",{"v":122773,"d":"122,773 "}," "," "," "," "," "," "," "," "," ",{"v":122773,"d":"122,773 "}," "]
["Other comprehensive income (loss), net of tax",{"v":-1235,"d":"(1,235)"}," "," "," "," "," "," "," "," "," "," ",{"v":-1235,"d":"(1,235)"}]
["Indirect repurchase of shares for minimum tax withholding (in shares)"," "," "," "," "," "," ",{"v":88,"d":"88 "}," "," "," "," "," "]
["Indirect repurchase of shares for minimum tax withholding",{"v":-7726,"d":"(7,726)"}," "," "," "," "," ",{"v":-7726,"d":"$ (7,726)"}," "," "," "," "," "]
["Restricted stock units and awards and performance share units (in shares)"," "," ",{"v":124,"d":"124 "}," ",{"v":78,"d":"78 "}," "," "," "," "," "," "," "]
["Restricted stock units and awards and performance share units"," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}," ",{"v":1,"d":"$ 1"},{"v":1,"d":"$ 1"}," "," ",{"v":-1,"d":"$ (1)"},{"v":-1,"d":"$ (1)"}," "," "]
["Stock-based compensation",{"v":5639,"d":"5,639 "}," "," "," "," "," "," ",{"v":5639,"d":"5,639 "}," "," "," "," "]
["Business acquisitions (in shares)"," "," "," ",{"v":3777,"d":"3,777 "}," "," "," "," "," "," "," "," "]
["Business acquisitions",{"v":15267,"d":"15,267 "}," "," ",{"v":38,"d":"$ 38"}," "," "," ",{"v":15229,"d":"15,229 "}," "," "," "," "]
["Common stock, ending balance (in shares) at Mar. 31, 2025"," "," "," ",{"v":141924,"d":"141,924 "}," "," "," "," "," "," "," "," "]
["Treasury stock, ending balance (in shares) at Mar. 31, 2025"," "," "," "," "," "," ",{"v":87835,"d":"87,835 "}," "," "," "," "," "]
["Ending balance at Mar. 31, 2025",{"v":1914701,"d":"$ 1,914,701"}," "," ",{"v":1420,"d":"$ 1,420"}," "," ",{"v":-918327,"d":"$ (918,327)"},{"v":1812729,"d":"$ 1,812,729"}," "," ",{"v":1018895,"d":"$ 1,018,895"},{"v":-16,"d":"$ (16)"}]

{"sheet":"CONDENSED CONSOLIDATED STATEM_3","index":4,"n_rows":43,"n_cols":3,"rows_kept":43,"merged":[[0,0,1,0],[0,1,0,2]]}
["CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Cash flows from operating activities:"," "," "]
["Net income",{"v":122773,"d":"$ 122,773"},{"v":76884,"d":"$ 76,884"}]
["Adjustments to reconcile net income to net cash used in operating activities:"," "," "]
["Depreciation and amortization expense",{"v":24791,"d":"24,791 "},{"v":9468,"d":"9,468 "}]
["Bad debt expense, net of recoveries",{"v":417,"d":"417 "},{"v":550,"d":"550 "}]
["Adjustment to contingent earnout liability",{"v":502,"d":"502 "},{"v":434,"d":"434 "}]
["Stock-based compensation expense",{"v":5639,"d":"5,639 "},{"v":2638,"d":"2,638 "}]
["Deferred income taxes",{"v":4320,"d":"4,320 "},{"v":2057,"d":"2,057 "}]
["Other, net",{"v":1009,"d":"1,009 "},{"v":150,"d":"150 "}]
["Changes in assets and liabilities, net of acquisitions and divestitures:"," "," "]
["Accounts receivable, net",{"v":-201258,"d":"(201,258)"},{"v":-121551,"d":"(121,551)"}]
["Other assets",{"v":-8990,"d":"(8,990)"},{"v":-2592,"d":"(2,592)"}]
["Accounts payable",{"v":11985,"d":"11,985 "},{"v":5743,"d":"5,743 "}]
["Income taxes payable",{"v":45626,"d":"45,626 "},{"v":24827,"d":"24,827 "}]
["Accrued personnel costs",{"v":-84642,"d":"(84,642)"},{"v":-62381,"d":"(62,381)"}]
["Other liabilities",{"v":-10438,"d":"(10,438)"},{"v":53,"d":"53 "}]
["Net cash used in operating activities",{"v":-88266,"d":"(88,266)"},{"v":-63720,"d":"(63,720)"}]
["Cash flows from investing activities:"," "," "]
["Business acquisitions and purchases of client lists, net of cash acquired",{"v":0,"d":"0 "},{"v":-21337,"d":"(21,337)"}]
["Purchases of client fund investments",{"v":-8300,"d":"(8,300)"},{"v":-4440,"d":"(4,440)"}]
["Proceeds from the sales and maturities of client fund investments",{"v":8410,"d":"8,410 "},{"v":5450,"d":"5,450 "}]
["Proceeds from sales of divested operations",{"v":289,"d":"289 "},{"v":0,"d":"0 "}]
["Change in funds held for clients",{"v":-91,"d":"(91)"},{"v":-1015,"d":"(1,015)"}]
["Additions to property and equipment",{"v":-5177,"d":"(5,177)"},{"v":-5121,"d":"(5,121)"}]
["Other, net",{"v":-92,"d":"(92)"},{"v":-2239,"d":"(2,239)"}]
["Net cash used in investing activities",{"v":-4961,"d":"(4,961)"},{"v":-28702,"d":"(28,702)"}]
["Cash flows from financing activities:"," "," "]
["Proceeds from bank debt",{"v":485600,"d":"485,600 "},{"v":381200,"d":"381,200 "}]
["Payment of bank debt",{"v":-358100,"d":"(358,100)"},{"v":-255800,"d":"(255,800)"}]
["Indirect repurchase of shares for minimum tax withholding",{"v":-7555,"d":"(7,555)"},{"v":-11229,"d":"(11,229)"}]
["Changes in client funds obligations",{"v":-35062,"d":"(35,062)"},{"v":-11859,"d":"(11,859)"}]
["Payment of contingent consideration for acquisitions and client lists",{"v":-29520,"d":"(29,520)"},{"v":-31124,"d":"(31,124)"}]
["Net cash provided by financing activities",{"v":55363,"d":"55,363 "},{"v":71188,"d":"71,188 "}]
["Net decrease in cash, cash equivalents and restricted cash",{"v":-37864,"d":"(37,864)"},{"v":-21234,"d":"(21,234)"}]
["Cash, cash equivalents and restricted cash at beginning of year",{"v":187170,"d":"187,170 "},{"v":157148,"d":"157,148 "}]
["Cash, cash equivalents and restricted cash at end of period",{"v":149306,"d":"149,306 "},{"v":135914,"d":"135,914 "}]
["Reconciliation of cash, cash equivalents and restricted cash to the Condensed Consolidated Balance Sheets:"," "," "]
["Cash and cash equivalents",{"v":8850,"d":"8,850 "},{"v":1402,"d":"1,402 "}]
["Restricted cash",{"v":40777,"d":"40,777 "},{"v":27740,"d":"27,740 "}]
["Cash equivalents included in funds held for clients",{"v":99679,"d":"99,679 "},{"v":106772,"d":"106,772 "}]
["Total cash, cash equivalents and restricted cash",{"v":149306,"d":"$ 149,306"},{"v":135914,"d":"$ 135,914"}]

{"sheet":"SUMMARY OF SIGNIFICANT ACCOUNTI","index":5,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Accounting Policies [Abstract]"," "]
["SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES","SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Selected Terms Used in Notes to the Condensed Consolidated Financial Statements ASA – Administrative Service Agreement ASC – Accounting Standards Codification ASU – Accounting Standards Update CPA firm – Certified Public Accounting firm FASB – The Financial Accounting Standards Board GAAP – United States Generally Accepted Accounting Principles SOFR – Secured Overnight Financing Rate SEC – United States Securities and Exchange Commission Marcum Acquisition - the Transaction Description of Business: CBIZ, Inc., together with all of its wholly-owned subsidiaries (\"CBIZ\", the \"Company\", \"we\", \"us\", or \"our\"), is a diversified services company which, acting through its subsidiaries, has been providing professional business services since 1996, primarily to small and medium-sized businesses, as well as individuals, governmental entities, and not-for-profit enterprises throughout the United States and parts of Canada. CBIZ, Inc. manages and reports its operations along three practice groups: Financial Services, Benefits and Insurance Services and National Practices. A further description of products and services offered by each of the practice groups is provided in Note 12, Segment Disclosures. In December of 2024, the Company formed CBIZ CC, LLC and CBIZ Campus One Cell, LLC (collectively “Captive Insurance Company”). CBIZ CC, LLC, a sponsored captive core, is not expected to have any underwriting activities. CBIZ Campus One Cell, LLC, a sponsored captive cell, provides stop-loss coverages to a group of higher education institutions who self-insure their medical and prescription drug benefits. The term of the insurance policy is one year, and the insured is billed at the beginning of each month for that month’s coverage. Registered in the State of Vermont, the Captive Insurance Company commenced operation on January 1, 2025. The Captive Insurance Company recognizes premium as revenue monthly as monthly coverage expires. For the three months ended March 31, 2025, revenue from the Captive Insurance Company was not material. Basis of Consolidation: The accompanying unaudited condensed consolidated financial statements include the operations of CBIZ, Inc. and all of its wholly-owned subsidiaries after elimination of all intercompany balances and transactions. We have determined that our relationship with certain CPA firms with which we maintain ASAs qualify as variable interest entities (\"VIEs\"), and we are the primary beneficiary of such VIE. The accompanying unaudited condensed consolidated financial statements do not reflect the operations or accounts of the VIEs as the impact is not material to the financial condition, results of operations, or cash flows of CBIZ. Unaudited Interim Financial Statements: The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2024. In the opinion of CBIZ management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2025. Use of Estimates: The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Changes in circumstances could cause actual results to differ materially from these estimates. Changes in Accounting Policies: We have consistently applied the accounting policies for the periods presented as described in Note 1, Basis of Presentation and Significant Accounting Policies, to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2024. Certain prior period amounts have been reclassified to conform to current year presentation."]

{"sheet":"NEW ACCOUNTING PRONOUNCEMENTS","index":6,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["NEW ACCOUNTING PRONOUNCEMENTS","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Accounting Changes and Error Corrections [Abstract]"," "]
["NEW ACCOUNTING PRONOUNCEMENTS","NEW ACCOUNTING PRONOUNCEMENTSThe FASB ASC is the sole source of authoritative GAAP other than the SEC issued rules and regulations that apply only to SEC registrants. The FASB issues an ASU to communicate changes to the FASB ASC. We assess and review the impact of all issued ASUs. During the three months ended March 31, 2025, we have implemented all new ASUs that are in effect and that may impact our consolidated financial statements."]

{"sheet":"BUSINESS COMBINATIONS","index":7,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["BUSINESS COMBINATIONS","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"," "]
["BUSINESS COMBINATIONS","BUSINESS COMBINATIONS Acquisition of Marcum LLP On November 1, 2024, the Company completed the acquisition of Marcum LLP (“Marcum”). The acquisition is referred to herein as the “Transaction”. During the three months ended March 31, 2025, the Company’s condensed consolidated statement of comprehensive income included $328.7 million of revenue and $86.5 million of operating income associated with the results of operations of Marcum. Stock Consideration Transferred At closing, the purchase price for the purpose of the Transaction consisted of an aggregate of $1,063.0 million of cash consideration and $934.7 million of the Company’s common stock, which represents a fair value of 13.6 million shares issued as stock consideration. Pursuant to the terms of the Transaction, with respect to the 13.6 million shares of stock consideration, approximately 4.0 million shares, in aggregate, were delivered from January 2, 2025 to April 1, 2025 to the selling shareholders. The remaining 9.6 million shares will be delivered in 32 monthly installments starting on May 1, 2025. Measurement Period Adjustments The Company applied the acquisition method of accounting in accordance with ASC 805, Business Combinations (“ASC 805”) and recognized assets acquired and liabilities assumed at their fair value as of the date of acquisition, with the excess purchase consideration recorded to goodwill. As the Company finalizes the estimation of the fair value of the assets acquired and liabilities assumed, additional adjustments may be recorded during the measurement period (a period not to exceed 12 months from the acquisition date). During the three months ended March 31, 2025, the Company reassessed its estimates and inputs as new information about facts and circumstances that existed as of the acquisition date became known. As a result, the Company recorded a measurement period adjustment to reduce goodwill by $20.2 million, of which $21.0 million reflected a reduction of the estimated settlement amounts associated with an acquired liability from $61.0 million to $40.0 million, and $0.8 million reflected other immaterial adjustments related to assets and liabilities previously unrecognized. The acquired liability was previously reported as a component of other non-current liabilities and was reclassified to \"other current liabilities\" as of March 31, 2025 due to the estimated timing of settlement. The following table summarizes the preliminary acquisition date fair value of net tangible and intangible assets acquired, net of liabilities assumed from Marcum, with the excess recorded as goodwill (in thousands): On November 1, 2024 Fair Value Total consideration transferred $ 1,997,781 Asset acquired: Account receivable 169,866 Unbilled revenue 23,247 Other current assets 25,829 Property and equipment 31,221 Other intangible assets 490,000 Right-of- use asset 164,970 Deferred income taxes, net 3,485 Total identifiable asset acquired 908,618 Liabilities assumed: Account payable 25,384 Accrued personnel costs 44,407 Other current liabilities 67,156 Contingent purchase price assumed (current and non-current) 25,042 Lease liabilities (current and non-current) 172,792 Other non-current liabilities 935 Total liabilities assumed 335,716 Net asset acquired 572,902 Goodwill $ 1,424,879 The preliminary purchase price allocation is subject to further refinement and may require adjustments to arrive at the final purchase price allocation. The above fair values of assets acquired and liabilities assumed are preliminary and are based on the information that was available as of the reporting date. The final determination of the fair value of certain assets and liabilities will be completed as soon as the necessary information, such as final working capital adjustments, becomes available but no later than one year from the acquisition date."]

{"sheet":"ACCOUNTS RECEIVABLE, NET","index":8,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["ACCOUNTS RECEIVABLE, NET","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Receivables [Abstract]"," "]
["ACCOUNTS RECEIVABLE, NET","ACCOUNTS RECEIVABLE, NET Accounts receivable, less allowance for doubtful accounts, reflects the net realizable value of receivables and approximates fair value. Unbilled revenue is recorded at estimated net realizable value. Assessing the collectability of the receivables (billed and unbilled) requires management judgment based on a combination of factors, including but not limited to, an evaluation of our historical incurred loss experience, credit-worthiness of our clients, age of the trade receivable balance, current economic conditions that may affect a client’s ability to pay, and reasonable and supportable forecasts. Receivables are charged-off against the allowance when the balance is deemed uncollectible. Accounts receivable, net, at March 31, 2025 and December 31, 2024 was as follows (in thousands): March 31, December 31, Trade accounts receivable $ 488,607 $ 416,211 Unbilled revenue, at net realizable value 290,448 150,362 Total accounts receivable 779,055 566,573 Allowance for doubtful accounts (43,629) (31,715) Accounts receivable, net $ 735,426 $ 534,858 Changes to the allowance for doubtful accounts for the three months ended March 31, 2025 and year ended December 31, 2024 were as follows (in thousands): March 31, December 31, Balance at beginning of period $ (31,715) $ (25,598) Provision (10,748) (19,979) Charge-offs, net of recoveries (1,166) 13,862 Allowance for doubtful accounts $ (43,629) $ (31,715)"]

{"sheet":"DEBT AND FINANCING ARRANGEMENTS","index":9,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["DEBT AND FINANCING ARRANGEMENTS","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Debt Disclosure [Abstract]"," "]
["DEBT AND FINANCING ARRANGEMENTS","DEBT AND FINANCING ARRANGEMENTS 2024 Credit Facilities - As of March 31, 2025, our primary financing arrangement is the 2024 Credit Facilities, which provides $2.0 billion in senior secured credit facilities, consisting of a $1.4 billion term loan (the “Term Loan”) and $600.0 million revolving credit facility (the “Revolving Credit Facility”). The 2024 Credit Facilities amend and restate the 2022 credit facility entered into on May 4, 2022 (the \"2022 Credit Facility\"). Th e 2024 Credit Facilities mature on November 1, 2029. The Term Loan provides for scheduled annual principal amortization payments of 5% in the first two years following closing, 7.5% annually in the third and fourth year following closing and 10% in the fifth year following closing, with the balance due at maturity. The 2024 Credit Facilities contain certain restrictive covenants customary for facilities of this type, including restrictions on indebtedness, liens or other encumbrances, making certain payments, investments, or to sell or otherwise dispose of a substantial portion of assets, or to merge or consolidate with an unaffiliated entity. The 2024 Credit Facilities also limits our ability to make dividend payments. Historically, we have not paid cash dividends on our common stock. Our Board of Directors has discretion over the payment and level of dividends on common stock, subject to the limitations of the 2024 Credit Facilities and applicable law. The 2024 Credit Facilities contain a provision that, in the event of a defined change in control, the 2024 Credit Facilities may be terminated. In addition, the 2024 Credit Facilities include a financial covenant requiring that Total Net Leverage Ratio not exceed 5.00 to 1.00 initially, stepping down in increments to 3.75 to 1.00 during and after the seventh fiscal quarter after the closing (with a limited ability to temporarily increase in connection with material acquisitions commencing in the sixth fiscal quarter after the closing). The 2024 Credit Facilities also require a Minimum Consolidated Interest Coverage Ratio of 3.00 to 1.00 and affirmative and negative covenants that are in each case generally similar to those contained in the 2022 Credit Facility, but with increases to certain baskets and caps and certain other exceptions. As of March 31, 2025 , we are in compliance with all covenants. The balance outstanding under the 2024 Credit Facilities at March 31, 2025 and December 31, 2024 was as follows (in thousands): March 31, 2025 December 31, 2024 Short-term debt Current portion Term Loan $ 70,000 $ 70,000 Current portion debt issuance costs, Term Loan (3,774) (3,823) Total short-term debt, net $ 66,226 $ 66,177 Long-term debt Revolver Facility $ 165,900 $ 20,900 Debt issuance costs, Revolver (6,836) (7,160) Long Term Portion Term Loan 1,312,500 1,330,000 Long Term Portion Debt Issuance Costs, Term Loan (9,060) (9,985) Total long-term debt, net $ 1,462,504 $ 1,333,755 The blended effective interest rates under the 2024 Credit Facilities and the 2022 Credit Facility, including the impact of interest rate swaps associated with those credit facilities, for the three months ended March 31, 2025 and 2024 were as follows: Three Months Ended 2025 2024 Weighted average rates 6.57% 5.23% Range of effective rates 3.18% - 8.75% 1.93% - 6.83% We had approximately $384 million of available funds under the 2024 Credit Facilities at March 31, 2025, based on the terms of the commitment. Available funds under the 2024 Credit Facilities are based on a multiple of earnings before interest, taxes, depreciation and amortization as defined in the 2024 Credit Facilities, and are reduced by letters of credit, other indebtedness and outstanding borrowings under the 2024 Credit Facilities. Under the 2024 Credit Facilities, loans are charged an interest rate consisting of a base rate or term SOFR rate plus an applicable margin, letters of credit are charged based on the same applicable margin, and a commitment fee is charged on the unused portion of the 2024 Credit Facilities. Refer to the Annual Report on Form 10-K for the year ended December 31, 2024 for further discussion on the 2024 Credit Facilities. Other Line of Credit - We have an unsecured $20.0 million line of credit by and among CBIZ Benefits and Insurance, Inc. and Huntington National Bank. We utilize this line to support our short-term funding requirements of payroll client fund obligations due to the investment of client funds, rather than liquidating client funds that have already been invested in available-for-sale securities. The line of credit did not have a balance outstanding at March 31, 2025 and December 31, 2024. On August 1, 2024, we renewed the line of credit and it will now terminate on July 31, 2025. Interest Expense "]

{"sheet":"COMMITMENTS AND CONTINGENCIES","index":10,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["COMMITMENTS AND CONTINGENCIES","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Commitments and Contingencies Disclosure [Abstract]"," "]
["COMMITMENTS AND CONTINGENCIES","COMMITMENTS AND CONTINGENCIES Letters of Credit and Guarantees - We provide letters of credit to landlords (lessors) of our leased premises in lieu of cash security deposits, which totaled $3.2 million and $3.2 million at March 31, 2025 and December 31, 2024, respectively. In addition, we provide license bonds to various state agencies to meet certain licensing requirements. The amount of license bonds outstanding was $2.2 million and $2.2 million at March 31, 2025 and December 31, 2024, respectively. Legal Proceedings - On December 19, 2016, CBIZ Operations, Inc. (\"CBIZ Operations\") was named as a defendant in a lawsuit filed by Zotec Partners, LLC (“Zotec”) in the Marion County Indiana Superior Court. After various amendments, the lawsuit asserted claims under Indiana law for securities, statutory and common law fraud or deception, unjust enrichment, breach of contract, and vicarious liability against CBIZ Operations and a former employee of CBIZ MMP in connection with the sale of the CBIZ MMP medical billing practice to Zotec. The plaintiff claimed that CBIZ Operations had a duty to disclose the fact, unknown to employees of CBIZ Operations at the time of the transaction, that the former employee had a financial arrangement with a Zotec vendor at the time CBIZ Operations sold CBIZ MMP to Zotec. The plaintiff sought damages of up to $177.0 million out of the $200.0 million transaction price. Trial was held in October 2021. The jury found in favor of CBIZ on all fraud, contract and other claims before it. On November 14, 2022, the trial court ruled in favor of CBIZ and against Zotec’s claim for statutory securities fraud. The court also ruled in favor of CBIZ on its counterclaim for indemnification under contract. The trial court conducted a hearing on December 12, 2023, to consider evidence regarding the amount of damages owed by Zotec to CBIZ on the counterclaim. On March 12, 2024, the court awarded CBIZ $3.1 million on its counterclaim. On April 10, 2024, Zotec filed a notice of appeal. On April 8, 2025, the Court of Appeals affirmed the trial court's dismissal of the securities fraud claim against CBIZ. The Court of Appeals reversed the award to CBIZ on its counterclaim. On November 10, 2023, CBIZ was named as a defendant in a putative class action lawsuit in the United States District Court for the District of Massachusetts by an individual claiming to be an employee of a CBIZ client whose personally identifiable information (“PII”) was compromised and stolen during a cyberattack CBIZ experienced on or about May 31, 2023. As a result of this incident, hackers were able to access and download certain files from CBIZ’s MOVEit Transfer server. The lawsuit alleges that CBIZ and Progress Software Corporation, the owner of MOVEit Transfer, failed to adequately secure and safeguard the individual’s, and similarly situated employees of CBIZ’s clients, PII from unauthorized access. The lawsuit seeks various remedies, including actual, compensatory, and punitive damages, along with injunctive relief, costs, and attorneys’ fees. On December 8, 2023, CBIZ was named as a defendant in a second putative class action lawsuit in the United States District Court for the District of Massachusetts by an individual making similar claims and seeking similar remedies as in the first lawsuit regarding the cyberattack CBIZ experienced on or about May 31, 2023. Both cases were transferred into a multidistrict litigation, styled as In Re: MOVEit Customer Data Security Breach Litigation, pending in the United States District Court for the District of Massachusetts (the “MDL”). To date, the MDL has over 180 cases against over 100 different defendants, all with claims arising out of the cyberbreach by hackers of Progress Software Corporation’s MOVEit Transfer software. The cases in the MDL, including the cases against CBIZ, are in their earliest stages, with a stay in place until the MDL Court issues a scheduling order. Due to the early stage of litigation, the Company is not able to determine or predict the ultimate outcome of these lawsuits nor reasonably provide an estimate or range of the possible outcome or losses, if any. In addition to the items disclosed above, the Company is, from time to time, subject to claims and lawsuits arising in the ordinary course of business. We cannot predict the outcome of all such matters or estimate the possible loss, if any. Although the proceedings are subject to uncertainties in the litigation process and the ultimate disposition of these proceedings is not presently determinable, we intend to vigorously defend these matters. Refer to the Annual Report on Form 10-K for the year ended December 31, 2024 for further discussion on the Company's commitments and contingencies."]

{"sheet":"FINANCIAL INSTRUMENTS","index":11,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["FINANCIAL INSTRUMENTS","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Investments, All Other Investments [Abstract]"," "]
["FINANCIAL INSTRUMENTS","FINANCIAL INSTRUMENTS Available-For-Sale Debt Securities - In connection with certain services provided by our payroll operations, we collect funds from our clients’ accounts in advance of paying client obligations. These funds held for clients are segregated and invested in accordance with our investment policy, which requires all investments carry an investment grade rating at the time of initial investment. These investments, primarily consisting of corporate and municipal bonds, are classified as available-for-sale and are included in the “Funds held for clients” line item on the accompanying unaudited Condensed Consolidated Balance Sheets. The par value of these investments totaled $41.0 million and $41.3 million at March 31, 2025 and December 31, 2024, respectively, and these investments have maturity or callable dates ranging from April 2025 through February 2028. At March 31, 2025, unrealized losses on the securities were not material and have not been recognized as a credit loss because the bonds are investment grade quality and management is not required or does not intend to sell prior to an expected recovery in value. The bond issuers continue to make timely principal and interest payments. The following table summarizes activities related to these investments for the three months ended March 31, 2025 and the year ended December 31, 2024 (in thousands): Three Months Ended March 31, 2025 Year Ended December 31, 2024 Fair value at beginning of period $ 40,999 $ 39,459 Purchases 8,300 23,210 Redemptions (1,400) (500) Maturities (7,010) (21,423) Change in bond premium 90 (386) Fair market value adjustment 102 639 Fair value at end of period $ 41,081 $ 40,999 In addition to the available-for-sale debt securities discussed above, we also held other depository assets in the amount of $0.2 million and $0.2 million at March 31, 2025 and December 31, 2024, respectively. Those depository assets are classified as Level 1 in the fair value hierarchy. Interest Rate Swaps - We utilize interest rate swaps to manage interest rate risk exposure associated with our floating-rate debt under the 2024 Credit Facilities, or the forecasted acquisition of such liability. We do not purchase or hold any derivative instruments for trading or speculative purposes. Refer to the Annual Report on Form 10-K for the year ended December 31, 2024 for further discussion on our interest rate swaps. The following table summarizes our outstanding interest rate swaps and their classification in the accompanying unaudited Condensed Consolidated Balance Sheets at March 31, 2025 and December 31, 2024 (amounts in thousands): March 31, 2025 Notional Fixed Rate Expiration Fair Balance Sheet Location Interest rate swap $ 50,000 0.834 % 4/14/2025 $ 67 Other current asset Interest rate swap $ 30,000 1.186 % 12/14/2026 $ 1,266 Other non-current asset Interest rate swap $ 20,000 2.450 % 8/14/2027 $ 549 Other non-current asset Interest rate swap $ 25,000 3.669 % 4/14/2028 $ (37) Other non-current liability Interest rate swap $ 25,000 4.488 % 10/14/2028 $ (710) Other non-current liability Interest rate swap (1) $ 50,000 3.703 % 3/14/2030 $ (189) Other non-current liability (1) Entered into during the first quarter of 2025. December 31, 2024 Notional Fixed Rate Expiration Fair Balance Sheet Location Interest rate swap $ 50,000 0.834 % 4/14/2025 $ 495 Other current asset Interest rate swap $ 30,000 1.186 % 12/14/2026 $ 1,604 Other non-current asset Interest rate swap $ 20,000 2.450 % 8/14/2027 $ 776 Other non-current asset Interest rate swap $ 25,000 3.669 % 4/14/2028 $ 243 Other non-current asset Interest rate swap $ 25,000 4.488 % 10/14/2028 $ (437) Other non-current liability Refer to Note 8, Fair Value Measurements, for additional disclosures regarding fair value measurements. The following table summarizes the effects of the interest rate swaps on the accompanying unaudited Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2025 and 2024 (in thousands): Gain (Loss) Recognized Gain Reclassified Three Months Ended Three Months Ended 2025 2024 2025 2024 Interest rate swaps $ (717) $ 1,854 $ 779 $ 1,191 "]

{"sheet":"FAIR VALUE MEASUREMENTS","index":12,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["FAIR VALUE MEASUREMENTS","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Fair Value Disclosures [Abstract]"," "]
["FAIR VALUE MEASUREMENTS","FAIR VALUE MEASUREMENTS The following table summarizes our assets and (liabilities) at March 31, 2025 and December 31, 2024, respectively, that are measured at fair value on a recurring basis subsequent to initial recognition and indicates the fair value hierarchy of the valuation techniques utilized by us to determine such fair value (in thousands): Level March 31, 2025 December 31, 2024 Assets of deferred compensation plan 1 $ 162,066 $ 167,170 Available-for-sale debt securities 1 41,081 40,999 Other depository assets 1 177 176 Deferred compensation plan obligations 1 (162,066) (167,170) Interest rate swaps 2 946 2,681 Bank debt 2 (1,528,730) (1,399,932) Contingent purchase price liabilities 3 (65,963) (96,967) During the three months ended March 31, 2025 and 2024, there were no transfers between the valuation hierarchy Levels 1, 2 and 3. The following table summarizes the change in Level 3 fair values of our contingent purchase price liabilities for the three months ended March 31, 2025 and 2024 (pre-tax basis, in thousands): 2025 2024 Beginning balance – December 31 $ (96,967) $ (114,946) Additions from business acquisitions (757) (13,522) Settlement of contingent purchase price liabilities 32,228 34,716 Change in fair value of contingencies 170 70 Change in net present value of contingencies (637) (504) Ending balance – March 31 $ (65,963) $ (94,186) The following table summarizes the changes in contingent purchase price consideration for previous acquisitions and contingent payments made for previous business acquisitions in the three months ended March 31, 2025 and 2024, respectively (in thousands): Three Months Ended March 31, 2025 2024 Net expense $ 467 $ 434 Cash settlement paid $ 29,520 $ 30,957 Shares issued (number) 33 60 "]

{"sheet":"OTHER COMPREHENSIVE INCOME","index":13,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["OTHER COMPREHENSIVE INCOME","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Equity [Abstract]"," "]
["OTHER COMPREHENSIVE INCOME","OTHER COMPREHENSIVE INCOME The following table is a summary of other comprehensive income and discloses the tax impact of each component of other comprehensive (loss) income for the three months ended March 31, 2025 and 2024 (in thousands): Three Months Ended 2025 2024 Net unrealized gain on available-for-sale securities, net of taxes (1) $ 72 $ 56 Net unrealized (loss) gain on interest rate swaps, net of taxes (2) (1,301) 960 Foreign currency translation (6) 2 Total other comprehensive (loss) income, net of tax $ (1,235) $ 1,018 (1) Net of income tax expense of $29 and $21 for the three months ended March 31, 2025 and 2024, respectively. (2)"]

{"sheet":"EMPLOYEE STOCK PLANS","index":14,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["EMPLOYEE STOCK PLANS","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Share-Based Payment Arrangement [Abstract]"," "]
["EMPLOYEE STOCK PLANS","EMPLOYEE STOCK PLANS On May 10, 2023, the shareholders of the Company approved an amendment to the 2019 Stock Omnibus Incentive Plan (the “2019 Plan”). The amendment added 1.5 million shares to the total number of shares that may be issued under the 2019 Plan. All other aspects of the 2019 Plan remain unchanged. The 2019 Plan, which expires in 2029, permits the grant of various forms of stock-based awards. A maximum of 4.6 million stock options, restricted stock or other stock-based compensation awards may be granted. The terms and vesting schedules for the stock-based awards vary by type and date of grant. Shares subject to award under the 2019 Plan may be either authorized but unissued shares of our common stock or treasury shares. Refer to the Annual Report on Form 10-K for the year ended December 31, 2024 for further discussion on the 2019 Plan. Compensation expense for stock-based awards recognized during the three months ended March 31, 2025 and 2024 was as follows (in thousands): Three Months Ended 2025 2024 Restricted stock units and awards $ 4,859 $ 1,351 Performance share units 780 1,287 Total stock-based compensation expense $ 5,639 $ 2,638 Stock Options and Restricted Stock Units and Awards – The Company did not grant any stock options, nor were any stock options exercised during the three months ended March 31, 2025. As of March 31, 2025, we have 150 thousand stock options outstanding with a weighted average exercise price per share of $35.22. The following table presents our restricted stock units and awards activity during the three months ended March 31, 2025 (in thousands, except per share data): Restricted Stock Units and Awards Number of Weighted Average Grant-Date Fair Value (1) Outstanding at beginning of year 899 $ 67.01 Granted 111 $ 81.64 Exercised or released (78) $ 49.87 Expired or canceled (3) $ 69.70 Outstanding at March 31, 2025 929 $ 70.20 (1) Represents weighted average market value of the shares; awards are granted at no cost to the recipients. Performance Share Units (“PSUs”) – PSUs are earned based on our financial performance over a contractual term of three years and the associated expense is recognized over that period based on the fair value of the award. A three-year cliff vesting schedule of the PSUs is dependent upon the Company’s performance relative to pre-established goals based on an earnings per share target (weighted 70%) and total growth in revenue (weighted 30%). The fair value of PSUs is calculated using the market value of a share of our common stock on the date of grant. For performance achieved above specified levels, the recipient may earn additional shares of stock, not to exceed 200% of the number of PSUs initially granted. For the PSUs granted in 2025, the recipients may earn additional shares of stock, not to exceed 300% of the number of PSUs initially granted if performance achieved above specified levels. The following table presents our PSUs activity during the three months ended March 31, 2025 (in thousands, except per share data): Performance Weighted Average Grant-Date Fair Value Per Unit (1) Outstanding at beginning of year 285 $ 48.18 Granted 81 $ 84.67 Vested (124) $ 38.12 Adjustments for performance results (3) $ 38.12 Outstanding at March 31, 2025 239 $ 65.80 (1) Represents weighted average market value of the PSUs; PSUs are granted at no cost to the recipients."]

{"sheet":"EARNINGS PER SHARE","index":15,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["EARNINGS PER SHARE","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Earnings Per Share [Abstract]"," "]
["EARNINGS PER SHARE","EARNINGS PER SHARE The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2025 and 2024 (in thousands, except per share data): Three Months Ended 2025 2024 Numerator: Net Income $ 122,773 $ 76,884 Denominator: Basic Weighted average common shares outstanding 63,843 50,045 Diluted Stock options (1) 84 74 Restricted stock units and awards (1) 215 99 Contingent shares (2) — 3 Diluted weighted average common shares outstanding (3) 64,142 50,221 Basic earnings per share $ 1.92 $ 1.54 Diluted earnings per share $ 1.91 $ 1.53 (1) A total of 44 thousand and 40 thousand shares of stock-based awards were excluded from the calculation of diluted earnings per share for three months ended March 31, 2025 and 2024 , respectively, as their effect would be anti-dilutive. (2) Contingent shares represent additional shares to be issued for purchase price earned by former owners of businesses acquired by us once future conditions have been met. (3) The denominator used in calculating diluted earnings per share did not include 239 thousand and 254 thousand PSUs for both the three months ended March 31, 2025, and 2024, respectively. The performance conditions associated with these PSUs were not met and consequently none of these PSUs were considered as issuable for the three months ended March 31, 2025 and 2024."]

{"sheet":"SEGMENT DISCLOSURES","index":16,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["SEGMENT DISCLOSURES","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Segment Reporting [Abstract]"," "]
["SEGMENT DISCLOSURES","SEGMENT DISCLOSURES Our business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The business units have been aggregated based on the following factors: similarity of the products and services provided to clients; similarity of the regulatory environment in which they operate; and similarity of economic conditions affecting long-term performance. The business units are managed along these segment lines. Refer to the Annual Report on Form 10-K for the year ended December 31, 2024 for further discussion on the segment lines. Corporate and Other - Included in Corporate and Other are operating expenses that are not directly allocated to the individual business units. These expenses primarily consist of certain health care costs, gains or losses attributable to assets held in our non-qualified deferred compensation plan, stock-based compensation, consolidation and integration charges, certain professional fees, certain advertising costs, and other various expenses. Accounting policies of the practice groups are the same as those described in Note 1, Basis of Presentation and Significant Accounting Policies, to the Annual Report on Form 10-K for the year ended December 31, 2024. Upon consolidation, intercompany accounts and transactions are eliminated, thus inter-segment revenue is not included in the measure of profit or loss for the practice groups. Performance of the practice groups is evaluated on income (loss) before income tax expense (benefit) excluding those costs listed above, which are reported in “Corporate and Other”. The practice groups respective revenue and pre-tax income, significant segment expenses, and a reconciliation of segment profit or loss measure to the consolidated income before income tax expense for the three months ended March 31, 2025 and 2024 is presented below. We do not manage our assets on a segment basis, therefore segment assets are not presented below. Segment information for the three months ended March 31, 2025 and 2024 was as follows (in thousands): Three months ended March 31, 2025 Financial Benefits and National Total Revenue from external customers $ 713,661 $ 112,976 $ 11,377 $ 838,014 Significant expenses: Personnel costs 411,302 66,665 10,155 488,122 Facility costs 23,710 3,208 2 26,920 Other costs, gains, and losses, net (1) 75,296 15,158 108 90,562 Total segment expense 510,308 85,031 10,265 605,604 Segment income before income tax expenses 203,353 27,945 1,112 232,410 Corporate & other: Unallocated corporate operating expenses 3,797 General & administrative expenses 28,070 Interest expense 25,156 Other expense, net 2,477 Consolidated income before income tax expenses $ 172,910 Three Months Ended March 31, 2024 Financial Benefits and National Total Revenue from external customers $ 372,630 $ 108,408 $ 13,259 $ 494,297 Significant expenses: Personnel costs 216,615 65,723 11,422 293,760 Facility costs 12,335 3,182 63 15,580 Other costs, gains, and losses, net (1) 36,525 14,688 448 51,661 Total segment expense 265,475 83,593 11,933 361,001 Segment income before income tax expenses 107,155 24,815 1,326 133,296 Corporate & other: Unallocated corporate operating expenses 15,354 General & administrative expenses 18,711 Interest expense 4,511 Other income, net (9,294) Consolidated income before income tax expenses $ 104,014 (1) Other costs, gains, and losses, net primarily consist of travel and entertainment costs, computer and technology related costs, depreciation and amortization expenses, and other discretionary costs."]

{"sheet":"SUBSEQUENT EVENTS","index":17,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["SUBSEQUENT EVENTS","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Subsequent Events [Abstract]"," "]
["SUBSEQUENT EVENTS","SUBSEQUENT EVENTSOn April 14, 2025, we entered into a 5-year interest rate swap with a notional value of $50 million and a fixed rate of 3.503%. The interest rate swap expires on April 14, 2030."]

{"sheet":"Pay vs Performance Disclosure","index":18,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Pay vs Performance Disclosure - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Pay vs Performance Disclosure"," "," "]
["Net income",{"v":122773,"d":"$ 122,773"},{"v":76884,"d":"$ 76,884"}]

{"sheet":"Insider Trading Arrangements","index":19,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Insider Trading Arrangements","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Trading Arrangements, by Individual"," "]
["Rule 10b5-1 Arrangement Adopted","false"]
["Non-Rule 10b5-1 Arrangement Adopted","false"]
["Rule 10b5-1 Arrangement Terminated","false"]
["Non-Rule 10b5-1 Arrangement Terminated","false"]

{"sheet":"SUMMARY OF SIGNIFICANT ACCOUN_2","index":20,"n_rows":9,"n_cols":2,"rows_kept":9,"merged":[[0,0,1,0]]}
["SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Accounting Policies [Abstract]"," "]
["Description of Business","Description of Business: CBIZ, Inc., together with all of its wholly-owned subsidiaries (\"CBIZ\", the \"Company\", \"we\", \"us\", or \"our\"), is a diversified services company which, acting through its subsidiaries, has been providing professional business services since 1996, primarily to small and medium-sized businesses, as well as individuals, governmental entities, and not-for-profit enterprises throughout the United States and parts of Canada. CBIZ, Inc. manages and reports its operations along three practice groups: Financial Services, Benefits and Insurance Services and National Practices. A further description of products and services offered by each of the practice groups is provided in Note 12, Segment Disclosures. In December of 2024, the Company formed CBIZ CC, LLC and CBIZ Campus One Cell, LLC (collectively “Captive Insurance Company”). CBIZ CC, LLC, a sponsored captive core, is not expected to have any underwriting activities. CBIZ Campus One Cell, LLC, a sponsored captive cell, provides stop-loss coverages to a group of higher education institutions who self-insure their medical and prescription drug benefits. The term of the insurance policy is one year, and the insured is billed at the beginning of each month for that month’s coverage. Registered in the State of Vermont, the Captive Insurance Company commenced operation on January 1, 2025. The Captive Insurance Company recognizes premium as revenue monthly as monthly coverage expires. For the three months ended March 31, 2025, revenue from the Captive Insurance Company was not material."]
["Basis of Consolidation","Basis of Consolidation: The accompanying unaudited condensed consolidated financial statements include the operations of CBIZ, Inc. and all of its wholly-owned subsidiaries after elimination of all intercompany balances and transactions. We have determined that our relationship with certain CPA firms with which we maintain ASAs qualify as variable interest entities (\"VIEs\"), and we are the primary beneficiary of such VIE. The accompanying unaudited condensed consolidated financial statements do not reflect the operations or accounts of the VIEs as the impact is not material to the financial condition, results of operations, or cash flows of CBIZ."]
["Unaudited Interim Financial Statements","Unaudited Interim Financial Statements: The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2024. In the opinion of CBIZ management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2025."]
["Use of Estimates","Use of Estimates: The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Changes in circumstances could cause actual results to differ materially from these estimates."]
["Changes in Accounting Policies","Changes in Accounting Policies: We have consistently applied the accounting policies for the periods presented as described in Note 1, Basis of Presentation and Significant Accounting Policies, to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2024. Certain prior period amounts have been reclassified to conform to current year presentation."]
["New Accounting Pronouncements","NEW ACCOUNTING PRONOUNCEMENTSThe FASB ASC is the sole source of authoritative GAAP other than the SEC issued rules and regulations that apply only to SEC registrants. The FASB issues an ASU to communicate changes to the FASB ASC. We assess and review the impact of all issued ASUs. During the three months ended March 31, 2025, we have implemented all new ASUs that are in effect and that may impact our consolidated financial statements."]

{"sheet":"BUSINESS COMBINATIONS (Tables)","index":21,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["BUSINESS COMBINATIONS (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"," "]
["Summary of Recognized Identified Assets Acquired and Liabilities Assumed","The following table summarizes the preliminary acquisition date fair value of net tangible and intangible assets acquired, net of liabilities assumed from Marcum, with the excess recorded as goodwill (in thousands): On November 1, 2024 Fair Value Total consideration transferred $ 1,997,781 Asset acquired: Account receivable 169,866 Unbilled revenue 23,247 Other current assets 25,829 Property and equipment 31,221 Other intangible assets 490,000 Right-of- use asset 164,970 Deferred income taxes, net 3,485 Total identifiable asset acquired 908,618 Liabilities assumed: Account payable 25,384 Accrued personnel costs 44,407 Other current liabilities 67,156 Contingent purchase price assumed (current and non-current) 25,042 Lease liabilities (current and non-current) 172,792 Other non-current liabilities 935 Total liabilities assumed 335,716 Net asset acquired 572,902 Goodwill $ 1,424,879 "]

{"sheet":"ACCOUNTS RECEIVABLE, NET (Table","index":22,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["ACCOUNTS RECEIVABLE, NET (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Receivables [Abstract]"," "]
["Summary of Accounts Receivable, Net","Accounts receivable, net, at March 31, 2025 and December 31, 2024 was as follows (in thousands): March 31, December 31, Trade accounts receivable $ 488,607 $ 416,211 Unbilled revenue, at net realizable value 290,448 150,362 Total accounts receivable 779,055 566,573 Allowance for doubtful accounts (43,629) (31,715) Accounts receivable, net $ 735,426 $ 534,858 "]
["Summary of Changes to the Allowance for Doubtful Accounts on Accounts Receivable","Changes to the allowance for doubtful accounts for the three months ended March 31, 2025 and year ended December 31, 2024 were as follows (in thousands): March 31, December 31, Balance at beginning of period $ (31,715) $ (25,598) Provision (10,748) (19,979) Charge-offs, net of recoveries (1,166) 13,862 Allowance for doubtful accounts $ (43,629) $ (31,715)"]

{"sheet":"DEBT AND FINANCING ARRANGEMEN_2","index":23,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["DEBT AND FINANCING ARRANGEMENTS (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Debt Disclosure [Abstract]"," "]
["Summary of Classification Between Short-Term and Long-Term Debt","The balance outstanding under the 2024 Credit Facilities at March 31, 2025 and December 31, 2024 was as follows (in thousands): March 31, 2025 December 31, 2024 Short-term debt Current portion Term Loan $ 70,000 $ 70,000 Current portion debt issuance costs, Term Loan (3,774) (3,823) Total short-term debt, net $ 66,226 $ 66,177 Long-term debt Revolver Facility $ 165,900 $ 20,900 Debt issuance costs, Revolver (6,836) (7,160) Long Term Portion Term Loan 1,312,500 1,330,000 Long Term Portion Debt Issuance Costs, Term Loan (9,060) (9,985) Total long-term debt, net $ 1,462,504 $ 1,333,755 "]
["Summary of Unsecured Credit Facility","The blended effective interest rates under the 2024 Credit Facilities and the 2022 Credit Facility, including the impact of interest rate swaps associated with those credit facilities, for the three months ended March 31, 2025 and 2024 were as follows: Three Months Ended 2025 2024 Weighted average rates 6.57% 5.23% Range of effective rates 3.18% - 8.75% 1.93% - 6.83%"]

{"sheet":"FINANCIAL INSTRUMENTS (Tables)","index":24,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["FINANCIAL INSTRUMENTS (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Investments, All Other Investments [Abstract]"," "]
["Summary of Activities Related to Investments","The following table summarizes activities related to these investments for the three months ended March 31, 2025 and the year ended December 31, 2024 (in thousands): Three Months Ended March 31, 2025 Year Ended December 31, 2024 Fair value at beginning of period $ 40,999 $ 39,459 Purchases 8,300 23,210 Redemptions (1,400) (500) Maturities (7,010) (21,423) Change in bond premium 90 (386) Fair market value adjustment 102 639 Fair value at end of period $ 41,081 $ 40,999 "]
["Summary of Outstanding Interest Rate Swaps","The following table summarizes our outstanding interest rate swaps and their classification in the accompanying unaudited Condensed Consolidated Balance Sheets at March 31, 2025 and December 31, 2024 (amounts in thousands): March 31, 2025 Notional Fixed Rate Expiration Fair Balance Sheet Location Interest rate swap $ 50,000 0.834 % 4/14/2025 $ 67 Other current asset Interest rate swap $ 30,000 1.186 % 12/14/2026 $ 1,266 Other non-current asset Interest rate swap $ 20,000 2.450 % 8/14/2027 $ 549 Other non-current asset Interest rate swap $ 25,000 3.669 % 4/14/2028 $ (37) Other non-current liability Interest rate swap $ 25,000 4.488 % 10/14/2028 $ (710) Other non-current liability Interest rate swap (1) $ 50,000 3.703 % 3/14/2030 $ (189) Other non-current liability (1) Entered into during the first quarter of 2025. December 31, 2024 Notional Fixed Rate Expiration Fair Balance Sheet Location Interest rate swap $ 50,000 0.834 % 4/14/2025 $ 495 Other current asset Interest rate swap $ 30,000 1.186 % 12/14/2026 $ 1,604 Other non-current asset Interest rate swap $ 20,000 2.450 % 8/14/2027 $ 776 Other non-current asset Interest rate swap $ 25,000 3.669 % 4/14/2028 $ 243 Other non-current asset Interest rate swap $ 25,000 4.488 % 10/14/2028 $ (437) Other non-current liability"]
["Summary of Effects of Interest Rate Swap","The following table summarizes the effects of the interest rate swaps on the accompanying unaudited Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2025 and 2024 (in thousands): Gain (Loss) Recognized Gain Reclassified Three Months Ended Three Months Ended 2025 2024 2025 2024 Interest rate swaps $ (717) $ 1,854 $ 779 $ 1,191 "]

{"sheet":"FAIR VALUE MEASUREMENTS (Tables","index":25,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["FAIR VALUE MEASUREMENTS (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Fair Value Disclosures [Abstract]"," "]
["Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis","The following table summarizes our assets and (liabilities) at March 31, 2025 and December 31, 2024, respectively, that are measured at fair value on a recurring basis subsequent to initial recognition and indicates the fair value hierarchy of the valuation techniques utilized by us to determine such fair value (in thousands): Level March 31, 2025 December 31, 2024 Assets of deferred compensation plan 1 $ 162,066 $ 167,170 Available-for-sale debt securities 1 41,081 40,999 Other depository assets 1 177 176 Deferred compensation plan obligations 1 (162,066) (167,170) Interest rate swaps 2 946 2,681 Bank debt 2 (1,528,730) (1,399,932) Contingent purchase price liabilities 3 (65,963) (96,967)"]
["Summary of Change in Level 3 Fair Values of Contingent Purchase Price Liabilities","The following table summarizes the change in Level 3 fair values of our contingent purchase price liabilities for the three months ended March 31, 2025 and 2024 (pre-tax basis, in thousands): 2025 2024 Beginning balance – December 31 $ (96,967) $ (114,946) Additions from business acquisitions (757) (13,522) Settlement of contingent purchase price liabilities 32,228 34,716 Change in fair value of contingencies 170 70 Change in net present value of contingencies (637) (504) Ending balance – March 31 $ (65,963) $ (94,186)"]
["Summary of Changes in Contingent Purchase Price Consideration","The following table summarizes the changes in contingent purchase price consideration for previous acquisitions and contingent payments made for previous business acquisitions in the three months ended March 31, 2025 and 2024, respectively (in thousands): Three Months Ended March 31, 2025 2024 Net expense $ 467 $ 434 Cash settlement paid $ 29,520 $ 30,957 Shares issued (number) 33 60 "]

{"sheet":"OTHER COMPREHENSIVE INCOME (Tab","index":26,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["OTHER COMPREHENSIVE INCOME (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Equity [Abstract]"," "]
["Summary of Other Comprehensive (Loss) Income and Tax Impact","The following table is a summary of other comprehensive income and discloses the tax impact of each component of other comprehensive (loss) income for the three months ended March 31, 2025 and 2024 (in thousands): Three Months Ended 2025 2024 Net unrealized gain on available-for-sale securities, net of taxes (1) $ 72 $ 56 Net unrealized (loss) gain on interest rate swaps, net of taxes (2) (1,301) 960 Foreign currency translation (6) 2 Total other comprehensive (loss) income, net of tax $ (1,235) $ 1,018 (1) Net of income tax expense of $29 and $21 for the three months ended March 31, 2025 and 2024, respectively. (2)"]

{"sheet":"EMPLOYEE STOCK PLANS (Tables)","index":27,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["EMPLOYEE STOCK PLANS (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Share-Based Payment Arrangement [Abstract]"," "]
["Summary of Compensation Expense for Stock-Based Awards","Compensation expense for stock-based awards recognized during the three months ended March 31, 2025 and 2024 was as follows (in thousands): Three Months Ended 2025 2024 Restricted stock units and awards $ 4,859 $ 1,351 Performance share units 780 1,287 Total stock-based compensation expense $ 5,639 $ 2,638 "]
["Summary of Restricted Stock Units and Awards Activity and Performance Share Units Activity","The following table presents our restricted stock units and awards activity during the three months ended March 31, 2025 (in thousands, except per share data): Restricted Stock Units and Awards Number of Weighted Average Grant-Date Fair Value (1) Outstanding at beginning of year 899 $ 67.01 Granted 111 $ 81.64 Exercised or released (78) $ 49.87 Expired or canceled (3) $ 69.70 Outstanding at March 31, 2025 929 $ 70.20 (1) The following table presents our PSUs activity during the three months ended March 31, 2025 (in thousands, except per share data): Performance Weighted Average Grant-Date Fair Value Per Unit (1) Outstanding at beginning of year 285 $ 48.18 Granted 81 $ 84.67 Vested (124) $ 38.12 Adjustments for performance results (3) $ 38.12 Outstanding at March 31, 2025 239 $ 65.80 (1) Represents weighted average market value of the PSUs; PSUs are granted at no cost to the recipients."]

{"sheet":"EARNINGS PER SHARE (Tables)","index":28,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["EARNINGS PER SHARE (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Earnings Per Share [Abstract]"," "]
["Summary of Computation of Basic and Diluted Earnings Per Share from Continuing Operations","The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2025 and 2024 (in thousands, except per share data): Three Months Ended 2025 2024 Numerator: Net Income $ 122,773 $ 76,884 Denominator: Basic Weighted average common shares outstanding 63,843 50,045 Diluted Stock options (1) 84 74 Restricted stock units and awards (1) 215 99 Contingent shares (2) — 3 Diluted weighted average common shares outstanding (3) 64,142 50,221 Basic earnings per share $ 1.92 $ 1.54 Diluted earnings per share $ 1.91 $ 1.53 (1) A total of 44 thousand and 40 thousand shares of stock-based awards were excluded from the calculation of diluted earnings per share for three months ended March 31, 2025 and 2024 , respectively, as their effect would be anti-dilutive. (2) Contingent shares represent additional shares to be issued for purchase price earned by former owners of businesses acquired by us once future conditions have been met. (3) The denominator used in calculating diluted earnings per share did not include 239 thousand and 254 thousand PSUs for both the three months ended March 31, 2025, and 2024, respectively. The performance conditions associated with these PSUs were not met and consequently none of these PSUs were considered as issuable for the three months ended March 31, 2025 and 2024."]

{"sheet":"SEGMENT DISCLOSURES (Tables)","index":29,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["SEGMENT DISCLOSURES (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Segment Reporting [Abstract]"," "]
["Summary of Segment Information","Segment information for the three months ended March 31, 2025 and 2024 was as follows (in thousands): Three months ended March 31, 2025 Financial Benefits and National Total Revenue from external customers $ 713,661 $ 112,976 $ 11,377 $ 838,014 Significant expenses: Personnel costs 411,302 66,665 10,155 488,122 Facility costs 23,710 3,208 2 26,920 Other costs, gains, and losses, net (1) 75,296 15,158 108 90,562 Total segment expense 510,308 85,031 10,265 605,604 Segment income before income tax expenses 203,353 27,945 1,112 232,410 Corporate & other: Unallocated corporate operating expenses 3,797 General & administrative expenses 28,070 Interest expense 25,156 Other expense, net 2,477 Consolidated income before income tax expenses $ 172,910 Three Months Ended March 31, 2024 Financial Benefits and National Total Revenue from external customers $ 372,630 $ 108,408 $ 13,259 $ 494,297 Significant expenses: Personnel costs 216,615 65,723 11,422 293,760 Facility costs 12,335 3,182 63 15,580 Other costs, gains, and losses, net (1) 36,525 14,688 448 51,661 Total segment expense 265,475 83,593 11,933 361,001 Segment income before income tax expenses 107,155 24,815 1,326 133,296 Corporate & other: Unallocated corporate operating expenses 15,354 General & administrative expenses 18,711 Interest expense 4,511 Other income, net (9,294) Consolidated income before income tax expenses $ 104,014 (1) Other costs, gains, and losses, net primarily consist of travel and entertainment costs, computer and technology related costs, depreciation and amortization expenses, and other discretionary costs."]

{"sheet":"SUMMARY OF SIGNIFICANT ACCOUN_3","index":30,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)","3 Months Ended"]
[null,"Mar. 31, 2025 practice_group"]
["Accounting Policies [Abstract]"," "]
["Number of practice groups",{"v":3,"d":"3 "}]

{"sheet":"BUSINESS COMBINATIONS - Additio","index":31,"n_rows":20,"n_cols":7,"rows_kept":20,"merged":[[0,0,1,0],[0,2,0,4]]}
["BUSINESS COMBINATIONS - Additional Information (Details) $ in Thousands, shares in Millions",null,"3 Months Ended"]
[null,"Nov. 01, 2024 USD ($) shares","Apr. 01, 2025 shares","Mar. 31, 2025 USD ($)","Mar. 31, 2024 USD ($)","Apr. 25, 2025 installment shares","Dec. 31, 2024 USD ($)"]
["Business Acquisition, Contingent Consideration [Line Items]"," "," "," "," "," "," "]
["Cash consideration"," "," ",{"v":0,"d":"$ 0"},{"v":21337,"d":"$ 21,337"}," "," "]
["Marcum LLP"," "," "," "," "," "," "]
["Business Acquisition, Contingent Consideration [Line Items]"," "," "," "," "," "," "]
["Revenues"," "," ",{"v":328700,"d":"328,700 "}," "," "," "]
["Operating income"," "," ",{"v":86500,"d":"86,500 "}," "," "," "]
["Cash consideration",{"v":1063000,"d":"$ 1,063,000"}," "," "," "," "," "]
["Common stock",{"v":934700,"d":"$ 934,700"}," "," "," "," "," "]
["Common stock issued (in shares) | shares",13.6," "," "," "," "," "]
["Reduction of goodwill"," "," ",{"v":20200,"d":"20,200 "}," "," "," "]
["Reduction of the estimated settlement amounts associated with acquired non-current liability"," "," ",{"v":21000,"d":"21,000 "}," "," "," "]
["Other non-current liabilities",{"v":935,"d":"$ 935"}," ",{"v":40000,"d":"40,000 "}," "," ",{"v":61000,"d":"$ 61,000"}]
["Other immaterial adjustments"," "," ",{"v":800,"d":"$ 800"}," "," "," "]
["Marcum LLP | Subsequent Event"," "," "," "," "," "," "]
["Business Acquisition, Contingent Consideration [Line Items]"," "," "," "," "," "," "]
["Business acquisitions (in shares) | shares"," ",{"v":4,"d":"4 "}," "," "," "," "]
["Remaining number of shares issuable (in shares) | shares"," "," "," "," ",9.6," "]
["Number of monthly installments for remaining shares issuable | installment"," "," "," "," ",{"v":32,"d":"32 "}," "]

{"sheet":"BUSINESS COMBINATIONS - Summary","index":32,"n_rows":22,"n_cols":4,"rows_kept":22}
["BUSINESS COMBINATIONS - Summary of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - Marcum LLP - USD ($) $ in Thousands","Nov. 01, 2024","Mar. 31, 2025","Dec. 31, 2024"]
["Business Acquisition [Line Items]"," "," "," "]
["Total consideration transferred",{"v":1997781,"d":"$ 1,997,781"}," "," "]
["Asset acquired:"," "," "," "]
["Account receivable",{"v":169866,"d":"169,866 "}," "," "]
["Unbilled revenue",{"v":23247,"d":"23,247 "}," "," "]
["Other current assets",{"v":25829,"d":"25,829 "}," "," "]
["Property and equipment",{"v":31221,"d":"31,221 "}," "," "]
["Other intangible assets",{"v":490000,"d":"490,000 "}," "," "]
["Right-of- use asset",{"v":164970,"d":"164,970 "}," "," "]
["Deferred income taxes, net",{"v":3485,"d":"3,485 "}," "," "]
["Total identifiable asset acquired",{"v":908618,"d":"908,618 "}," "," "]
["Liabilities assumed:"," "," "," "]
["Account payable",{"v":25384,"d":"25,384 "}," "," "]
["Accrued personnel costs",{"v":44407,"d":"44,407 "}," "," "]
["Other current liabilities",{"v":67156,"d":"67,156 "}," "," "]
["Contingent purchase price assumed (current and non-current)",{"v":25042,"d":"25,042 "}," "," "]
["Lease liabilities (current and non-current)",{"v":172792,"d":"172,792 "}," "," "]
["Other non-current liabilities",{"v":935,"d":"935 "},{"v":40000,"d":"$ 40,000"},{"v":61000,"d":"$ 61,000"}]
["Total liabilities assumed",{"v":335716,"d":"335,716 "}," "," "]
["Net asset acquired",{"v":572902,"d":"572,902 "}," "," "]
["Goodwill",{"v":1424879,"d":"$ 1,424,879"}," "," "]

{"sheet":"ACCOUNTS RECEIVABLE, NET - Summ","index":33,"n_rows":7,"n_cols":4,"rows_kept":7}
["ACCOUNTS RECEIVABLE, NET - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024","Dec. 31, 2023"]
["Receivables [Abstract]"," "," "," "]
["Trade accounts receivable",{"v":488607,"d":"$ 488,607"},{"v":416211,"d":"$ 416,211"}," "]
["Unbilled revenue, at net realizable value",{"v":290448,"d":"290,448 "},{"v":150362,"d":"150,362 "}," "]
["Total accounts receivable",{"v":779055,"d":"779,055 "},{"v":566573,"d":"566,573 "}," "]
["Allowance for doubtful accounts",{"v":-43629,"d":"(43,629)"},{"v":-31715,"d":"(31,715)"},{"v":-25598,"d":"$ (25,598)"}]
["Accounts receivable, net",{"v":735426,"d":"$ 735,426"},{"v":534858,"d":"$ 534,858"}," "]

{"sheet":"ACCOUNTS RECEIVABLE, NET - Su_2","index":34,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0]]}
["ACCOUNTS RECEIVABLE, NET - Summary of Changes to the Allowance for Doubtful Accounts on Accounts Receivable (Details) - USD ($) $ in Thousands","3 Months Ended","12 Months Ended"]
[null,"Mar. 31, 2025","Dec. 31, 2024"]
["Accounts Receivable, Allowance for Credit Loss [Roll Forward]"," "," "]
["Balance at beginning of period",{"v":-31715,"d":"$ (31,715)"},{"v":-25598,"d":"$ (25,598)"}]
["Provision",{"v":-10748,"d":"(10,748)"},{"v":-19979,"d":"(19,979)"}]
["Charge-offs, net of recoveries",{"v":-1166,"d":"(1,166)"},{"v":13862,"d":"13,862 "}]
["Allowance for doubtful accounts",{"v":-43629,"d":"$ (43,629)"},{"v":-31715,"d":"$ (31,715)"}]

{"sheet":"DEBT AND FINANCING ARRANGEMEN_3","index":35,"n_rows":26,"n_cols":4,"rows_kept":26,"merged":[[0,0,1,0],[0,1,0,2]]}
["DEBT AND FINANCING ARRANGEMENTS - Additional Information (Details) - USD ($)","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Debt Instrument [Line Items]"," "," "," "]
["Interest expense",{"v":25156000,"d":"$ 25,156,000"},{"v":4511000,"d":"$ 4,511,000"}," "]
["Line of Credit"," "," "," "]
["Debt Instrument [Line Items]"," "," "," "]
["Line of credit facility, maximum borrowing capacity",{"v":20000000,"d":"20,000,000 "}," "," "]
["Outstanding line of credit",{"v":0,"d":"0 "}," ",{"v":0,"d":"$ 0"}]
["2024 Credit Facilities"," "," "," "]
["Debt Instrument [Line Items]"," "," "," "]
["Available funds under credit facility",{"v":384000000,"d":"384,000,000 "}," "," "]
["2024 Credit Facilities | Line of Credit"," "," "," "]
["Debt Instrument [Line Items]"," "," "," "]
["Line of credit facility, maximum borrowing capacity",{"v":2000000000,"d":"$ 2,000,000,000"}," "," "]
["Annual amortization rate first two years",{"v":0.05,"d":"5%"}," "," "]
["Annual amortization rate third and fourth years",{"v":0.075,"d":"7.50%"}," "," "]
["Annual amortization rate, year five",{"v":0.1,"d":"10%"}," "," "]
["Covenant leverage ratio, maximum, tranche one",{"v":5,"d":"5 "}," "," "]
["Covenant leverage ratio, maximum, tranche two",3.75," "," "]
["Covenant interest coverage ratio, minimum",{"v":3,"d":"3 "}," "," "]
["2024 Credit Facilities | Line of Credit | Secured Debt"," "," "," "]
["Debt Instrument [Line Items]"," "," "," "]
["Line of credit facility, maximum borrowing capacity",{"v":1400000000,"d":"$ 1,400,000,000"}," "," "]
["2024 Credit Facilities | Line of Credit | Revolving Credit Facility"," "," "," "]
["Debt Instrument [Line Items]"," "," "," "]
["Line of credit facility, maximum borrowing capacity",{"v":600000000,"d":"$ 600,000,000"}," "," "]

{"sheet":"DEBT AND FINANCING ARRANGEMEN_4","index":36,"n_rows":18,"n_cols":4,"rows_kept":18,"merged":[[0,0,0,1],[16,0,16,2],[17,0,17,2]]}
["DEBT AND FINANCING ARRANGEMENTS - Summary of Classification Between Short-Term and Long-Term Debt (Details) - USD ($) $ in Thousands",null,"Mar. 31, 2025","Dec. 31, 2024"]
["Short-term debt",null," "," "]
["Total short-term debt, net","[1]",{"v":66226,"d":"$ 66,226"},{"v":66177,"d":"$ 66,177"}]
["Long-term debt",null," "," "]
["Total long-term debt, net","[1]",{"v":1462504,"d":"1,462,504 "},{"v":1333755,"d":"1,333,755 "}]
["Secured Debt",null," "," "]
["Short-term debt",null," "," "]
["Current portion Term Loan",null,{"v":70000,"d":"70,000 "},{"v":70000,"d":"70,000 "}]
["Current portion debt issuance costs, Term Loan",null,{"v":-3774,"d":"(3,774)"},{"v":-3823,"d":"(3,823)"}]
["Long-term debt",null," "," "]
["Long-term line of credit",null,{"v":1312500,"d":"1,312,500 "},{"v":1330000,"d":"1,330,000 "}]
["Debt issuance costs, noncurrent",null,{"v":-9060,"d":"(9,060)"},{"v":-9985,"d":"(9,985)"}]
["Revolving Credit Facility",null," "," "]
["Long-term debt",null," "," "]
["Long-term line of credit",null,{"v":165900,"d":"165,900 "},{"v":20900,"d":"20,900 "}]
["Debt issuance costs, noncurrent",null,{"v":-6836,"d":"$ (6,836)"},{"v":-7160,"d":"$ (7,160)"}]
[]
["[1] Reflects the net debt for the Term Loan and Revolver with the associated debt issuance costs in short-term and long-term liabilities. See Note 5. Debt and Financing Arrangements for further discussion of the short-term and long-term debt."]

{"sheet":"DEBT AND FINANCING ARRANGEMEN_5","index":37,"n_rows":9,"n_cols":3,"rows_kept":9}
["DEBT AND FINANCING ARRANGEMENTS - Summary of Unsecured Credit Facility (Details) - Line of credit","Mar. 31, 2025","Mar. 31, 2024"]
["Debt Instrument [Line Items]"," "," "]
["Weighted average rates",{"v":0.0657,"d":"6.57%"},{"v":0.0523,"d":"5.23%"}]
["Minimum"," "," "]
["Debt Instrument [Line Items]"," "," "]
["Range of effective rates",{"v":0.0318,"d":"3.18%"},{"v":0.0193,"d":"1.93%"}]
["Maximum"," "," "]
["Debt Instrument [Line Items]"," "," "]
["Range of effective rates",{"v":0.0875,"d":"8.75%"},{"v":0.0683,"d":"6.83%"}]

{"sheet":"COMMITMENTS AND CONTINGENCIES -","index":38,"n_rows":4,"n_cols":3,"rows_kept":4}
["COMMITMENTS AND CONTINGENCIES - Letters of Credit and Guarantees (Narrative) (Details) - USD ($) $ in Millions","Mar. 31, 2025","Dec. 31, 2024"]
["Commitments and Contingencies Disclosure [Abstract]"," "," "]
["Letters of credit outstanding",{"v":3.2,"d":"$ 3.2"},{"v":3.2,"d":"$ 3.2"}]
["License bonds outstanding amount",{"v":2.2,"d":"$ 2.2"},{"v":2.2,"d":"$ 2.2"}]

{"sheet":"COMMITMENTS AND CONTINGENCIES_2","index":39,"n_rows":13,"n_cols":4,"rows_kept":13,"merged":[[0,0,1,0]]}
["COMMITMENTS AND CONTINGENCIES - Legal Proceedings (Narrative) (Details) $ in Millions",null,null,"3 Months Ended"]
[null,"Mar. 12, 2024 USD ($)","Dec. 19, 2016 USD ($)","Mar. 31, 2025 claim defendant"]
["CBIZ Operations and a former employee of CBIZ MMP"," "," "," "]
["Commitments And Contingencies [Line Items]"," "," "," "]
["Total transaction price"," ",{"v":200,"d":"$ 200"}," "]
["Litigation settlement, amount awarded",{"v":3.1,"d":"$ 3.1"}," "," "]
["CBIZ Operations and a former employee of CBIZ MMP | Maximum"," "," "," "]
["Commitments And Contingencies [Line Items]"," "," "," "]
["Amount of damages sought (up to)"," ",{"v":177,"d":"$ 177"}," "]
["MOVEit Customer Data Security Breach Litigation"," "," "," "]
["Commitments And Contingencies [Line Items]"," "," "," "]
["Number of claims filed | claim"," "," ",{"v":180,"d":"180 "}]
["Number of defendants | defendant"," "," ",{"v":100,"d":"100 "}]

{"sheet":"FINANCIAL INSTRUMENTS - Additio","index":40,"n_rows":7,"n_cols":3,"rows_kept":7}
["FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Debt Securities, Available-for-sale [Line Items]"," "," "]
["Par value of available-for-sale debt securities",{"v":41000,"d":"$ 41,000"},{"v":41300,"d":"$ 41,300"}]
["Funds held for clients",{"v":140932,"d":"140,932 "},{"v":175853,"d":"175,853 "}]
["Certified Deposits and Other Depository Assets"," "," "]
["Debt Securities, Available-for-sale [Line Items]"," "," "]
["Funds held for clients",{"v":200,"d":"$ 200"},{"v":200,"d":"$ 200"}]

{"sheet":"FINANCIAL INSTRUMENTS - Summary","index":41,"n_rows":10,"n_cols":3,"rows_kept":10,"merged":[[0,0,1,0]]}
["FINANCIAL INSTRUMENTS - Summary of Activities Related to Investments (Details) - USD ($) $ in Thousands","3 Months Ended","12 Months Ended"]
[null,"Mar. 31, 2025","Dec. 31, 2024"]
["Debt Securities, Available for Sale [Roll Forward]"," "," "]
["Fair value at beginning of period",{"v":40999,"d":"$ 40,999"},{"v":39459,"d":"$ 39,459"}]
["Purchases",{"v":8300,"d":"8,300 "},{"v":23210,"d":"23,210 "}]
["Redemptions",{"v":-1400,"d":"(1,400)"},{"v":-500,"d":"(500)"}]
["Maturities",{"v":-7010,"d":"(7,010)"},{"v":-21423,"d":"(21,423)"}]
["Change in bond premium",{"v":90,"d":"90 "},{"v":-386,"d":"(386)"}]
["Fair market value adjustment",{"v":102,"d":"102 "},{"v":639,"d":"639 "}]
["Fair value at end of period",{"v":41081,"d":"$ 41,081"},{"v":40999,"d":"$ 40,999"}]

{"sheet":"FINANCIAL INSTRUMENTS - Summa_2","index":42,"n_rows":36,"n_cols":3,"rows_kept":36}
["FINANCIAL INSTRUMENTS - Summary of Outstanding Interest Rate Swaps (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Interest Rate Swap, April 2025 Expiration | Other current asset"," "," "]
["Derivatives, Fair Value [Line Items]"," "," "]
["Notional amount, asset",{"v":50000,"d":"$ 50,000"},{"v":50000,"d":"$ 50,000"}]
["Interest rate swap, fixed interest rate",{"v":0.00834,"d":"0.834%"},{"v":0.00834,"d":"0.834%"}]
["Fair value, asset",{"v":67,"d":"$ 67"},{"v":495,"d":"$ 495"}]
["Interest Rate Swap, December 2026 Expiration | Other non-current asset"," "," "]
["Derivatives, Fair Value [Line Items]"," "," "]
["Notional amount, asset",{"v":30000,"d":"$ 30,000"},{"v":30000,"d":"$ 30,000"}]
["Interest rate swap, fixed interest rate",{"v":0.01186,"d":"1.186%"},{"v":0.01186,"d":"1.186%"}]
["Fair value, asset",{"v":1266,"d":"$ 1,266"},{"v":1604,"d":"$ 1,604"}]
["Interest Rate Swap, August 2027 Expiration | Other non-current asset"," "," "]
["Derivatives, Fair Value [Line Items]"," "," "]
["Notional amount, asset",{"v":20000,"d":"$ 20,000"},{"v":20000,"d":"$ 20,000"}]
["Interest rate swap, fixed interest rate",{"v":0.0245,"d":"2.45%"},{"v":0.0245,"d":"2.45%"}]
["Fair value, asset",{"v":549,"d":"$ 549"},{"v":776,"d":"$ 776"}]
["Interest Rate Swap, April 2028 Expiration | Other non-current asset"," "," "]
["Derivatives, Fair Value [Line Items]"," "," "]
["Notional amount, asset"," ",{"v":25000,"d":"$ 25,000"}]
["Interest rate swap, fixed interest rate"," ",{"v":0.03669,"d":"3.669%"}]
["Fair value, asset"," ",{"v":243,"d":"$ 243"}]
["Interest Rate Swap, April 2028 Expiration | Other non-current liability"," "," "]
["Derivatives, Fair Value [Line Items]"," "," "]
["Notional amount, liability",{"v":25000,"d":"$ 25,000"}," "]
["Interest rate swap, fixed interest rate",{"v":0.03669,"d":"3.669%"}," "]
["Fair value, liability",{"v":-37,"d":"$ (37)"}," "]
["Interest Rate Swap, October 2028 Expiration | Other non-current liability"," "," "]
["Derivatives, Fair Value [Line Items]"," "," "]
["Notional amount, liability",{"v":25000,"d":"$ 25,000"},{"v":25000,"d":"$ 25,000"}]
["Interest rate swap, fixed interest rate",{"v":0.04488,"d":"4.488%"},{"v":0.04488,"d":"4.488%"}]
["Fair value, liability",{"v":-710,"d":"$ (710)"},{"v":-437,"d":"$ (437)"}]
["Interest Rate Swap, March 2030 Expiration | Other non-current liability"," "," "]
["Derivatives, Fair Value [Line Items]"," "," "]
["Notional amount, liability",{"v":50000,"d":"$ 50,000"}," "]
["Interest rate swap, fixed interest rate",{"v":0.03703,"d":"3.703%"}," "]
["Fair value, liability",{"v":-189,"d":"$ (189)"}," "]

{"sheet":"FINANCIAL INSTRUMENTS - Summa_3","index":43,"n_rows":8,"n_cols":3,"rows_kept":8,"merged":[[0,0,1,0],[0,1,0,2]]}
["FINANCIAL INSTRUMENTS - Summary of Effects of Interest Rate Swap (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Derivatives, Fair Value [Line Items]"," "," "]
["Gain (Loss) Recognized in AOCI, net of tax",{"v":-1301,"d":"$ (1,301)"},{"v":960,"d":"$ 960"}]
["Interest rate swaps"," "," "]
["Derivatives, Fair Value [Line Items]"," "," "]
["Gain (Loss) Recognized in AOCI, net of tax",{"v":-717,"d":"(717)"},{"v":1854,"d":"1,854 "}]
["Gain Reclassified from AOCI into Expense",{"v":779,"d":"$ 779"},{"v":1191,"d":"$ 1,191"}]

{"sheet":"FAIR VALUE MEASUREMENTS - Summa","index":44,"n_rows":18,"n_cols":4,"rows_kept":18}
["FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024","Dec. 31, 2023"]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"," "," "," "]
["Assets of deferred compensation plan",{"v":162066,"d":"$ 162,066"},{"v":167170,"d":"$ 167,170"}," "]
["Available-for-sale debt securities",{"v":41081,"d":"41,081 "},{"v":40999,"d":"40,999 "},{"v":39459,"d":"$ 39,459"}]
["Deferred compensation plan obligations",{"v":-162066,"d":"(162,066)"},{"v":-167170,"d":"(167,170)"}," "]
["Level 1"," "," "," "]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"," "," "," "]
["Assets of deferred compensation plan",{"v":162066,"d":"162,066 "},{"v":167170,"d":"167,170 "}," "]
["Available-for-sale debt securities",{"v":41081,"d":"41,081 "},{"v":40999,"d":"40,999 "}," "]
["Other depository assets",{"v":177,"d":"177 "},{"v":176,"d":"176 "}," "]
["Deferred compensation plan obligations",{"v":-162066,"d":"(162,066)"},{"v":-167170,"d":"(167,170)"}," "]
["Level 2"," "," "," "]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"," "," "," "]
["Interest rate swaps",{"v":946,"d":"946 "},{"v":2681,"d":"2,681 "}," "]
["Bank debt",{"v":-1528730,"d":"(1,528,730)"},{"v":-1399932,"d":"(1,399,932)"}," "]
["Level 3"," "," "," "]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"," "," "," "]
["Contingent purchase price liabilities",{"v":-65963,"d":"$ (65,963)"},{"v":-96967,"d":"$ (96,967)"}," "]

{"sheet":"FAIR VALUE MEASUREMENTS - Sum_2","index":45,"n_rows":9,"n_cols":3,"rows_kept":9,"merged":[[0,0,1,0],[0,1,0,2]]}
["FAIR VALUE MEASUREMENTS - Summary of Change in Level 3 Fair Values of Contingent Purchase Price Liabilities (Details) - Contingent Purchase Price Liabilities - Level 3 - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"," "," "]
["Beginning balance",{"v":-96967,"d":"$ (96,967)"},{"v":-114946,"d":"$ (114,946)"}]
["Additions from business acquisitions",{"v":-757,"d":"(757)"},{"v":-13522,"d":"(13,522)"}]
["Settlement of contingent purchase price liabilities",{"v":32228,"d":"32,228 "},{"v":34716,"d":"34,716 "}]
["Change in fair value of contingencies",{"v":170,"d":"170 "},{"v":70,"d":"70 "}]
["Change in net present value of contingencies",{"v":-637,"d":"(637)"},{"v":-504,"d":"(504)"}]
["Ending balance",{"v":-65963,"d":"$ (65,963)"},{"v":-94186,"d":"$ (94,186)"}]

{"sheet":"FAIR VALUE MEASUREMENTS - Sum_3","index":46,"n_rows":6,"n_cols":3,"rows_kept":6,"merged":[[0,0,1,0],[0,1,0,2]]}
["FAIR VALUE MEASUREMENTS - Summary of Changes in Contingent Purchase Price Consideration (Details) - USD ($) shares in Thousands, $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Fair Value Disclosures [Abstract]"," "," "]
["Net expense",{"v":467,"d":"$ 467"},{"v":434,"d":"$ 434"}]
["Cash settlement paid",{"v":29520,"d":"$ 29,520"},{"v":30957,"d":"$ 30,957"}]
["Shares issued (number)",{"v":33,"d":"33 "},{"v":60,"d":"60 "}]

{"sheet":"OTHER COMPREHENSIVE INCOME (Det","index":47,"n_rows":9,"n_cols":3,"rows_kept":9,"merged":[[0,0,1,0],[0,1,0,2]]}
["OTHER COMPREHENSIVE INCOME (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Equity [Abstract]"," "," "]
["Net unrealized gain on available-for-sale securities, net of taxes",{"v":72,"d":"$ 72"},{"v":56,"d":"$ 56"}]
["Net unrealized (loss) gain on interest rate swaps, net of taxes",{"v":-1301,"d":"(1,301)"},{"v":960,"d":"960 "}]
["Foreign currency translation",{"v":-6,"d":"(6)"},{"v":2,"d":"2 "}]
["Total other comprehensive (loss) income, net of tax",{"v":-1235,"d":"(1,235)"},{"v":1018,"d":"1,018 "}]
["Unrealized gain (loss) on available-for-sale securities, income tax expense",{"v":29,"d":"29 "},{"v":21,"d":"21 "}]
["Unrealized gain (loss) on interest rate swaps, income tax expense (benefit)",{"v":-434,"d":"$ (434)"},{"v":322,"d":"$ 322"}]

{"sheet":"EMPLOYEE STOCK PLANS - Addition","index":48,"n_rows":21,"n_cols":3,"rows_kept":21,"merged":[[0,0,1,0]]}
["EMPLOYEE STOCK PLANS - Additional Information (Details) - $ / shares","3 Months Ended"]
[null,"Mar. 31, 2025","May 10, 2023"]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "]
["Granted (in shares)",{"v":0,"d":"0 "}," "]
["Stock options exercised (in shares)",{"v":0,"d":"0 "}," "]
["Stock options outstanding (in shares)",{"v":150000,"d":"150,000 "}," "]
["Weighted average exercise price (in dollars per share)",{"v":35.22,"d":"$ 35.22"}," "]
["Performance share units"," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "]
["Share-based compensation arrangement by share-based payment award, remaining contractual term","3 years"," "]
["Performance share units, vesting period","3 years"," "]
["Achievement of an earnings per share target",{"v":0.7,"d":"70%"}," "]
["Achievement of total growth in revenue",{"v":0.3,"d":"30%"}," "]
["Performance share units | Maximum"," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "]
["Percentage of initial grant, tranche one",{"v":2,"d":"200%"}," "]
["Percentage of initial grant, tranche two",{"v":3,"d":"300%"}," "]
["2019 Plan"," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "]
["Additional shares authorized for issuance (in shares)"," ",{"v":1500000,"d":"1,500,000 "}]
["Maximum stock based compensation awards granted under the plan (in shares)"," ",{"v":4600000,"d":"4,600,000 "}]

{"sheet":"EMPLOYEE STOCK PLANS - Summary ","index":49,"n_rows":6,"n_cols":3,"rows_kept":6,"merged":[[0,0,1,0],[0,1,0,2]]}
["EMPLOYEE STOCK PLANS - Summary of Compensation Expense for Stock-Based Awards (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Share-Based Payment Arrangement [Abstract]"," "," "]
["Restricted stock units and awards",{"v":4859,"d":"$ 4,859"},{"v":1351,"d":"$ 1,351"}]
["Performance share units",{"v":780,"d":"780 "},{"v":1287,"d":"1,287 "}]
["Total stock-based compensation expense",{"v":5639,"d":"$ 5,639"},{"v":2638,"d":"$ 2,638"}]

{"sheet":"EMPLOYEE STOCK PLANS - Summar_2","index":50,"n_rows":14,"n_cols":2,"rows_kept":14,"merged":[[0,0,1,0]]}
["EMPLOYEE STOCK PLANS - Summary of Restricted Stock Units and Awards Activity (Details) - Restricted Stock Units and Awards shares in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025 $ / shares shares"]
["Number of Shares"," "]
["Outstanding at beginning of period (in shares) | shares",{"v":899,"d":"899 "}]
["Granted (in shares) | shares",{"v":111,"d":"111 "}]
["Exercised or released (in shares) | shares",{"v":-78,"d":"(78)"}]
["Expired or canceled (in shares) | shares",{"v":-3,"d":"(3)"}]
["Outstanding at end of period (in shares) | shares",{"v":929,"d":"929 "}]
["Weighted Average Grant-Date Fair Value"," "]
["Outstanding at beginning of period (in dollars per share) | $ / shares",{"v":67.01,"d":"$ 67.01"}]
["Granted (in dollars per share) | $ / shares",81.64]
["Exercised or released (in dollars per share) | $ / shares",49.87]
["Expired or canceled (in dollars per share) | $ / shares",{"v":69.7,"d":"69.70"}]
["Outstanding at end of period (in dollars per share) | $ / shares",{"v":70.2,"d":"$ 70.20"}]

{"sheet":"EMPLOYEE STOCK PLANS - Summar_3","index":51,"n_rows":14,"n_cols":2,"rows_kept":14,"merged":[[0,0,1,0]]}
["EMPLOYEE STOCK PLANS - Summary of Performance Share Units Activity (Details) - Performance share units shares in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025 $ / shares shares"]
["Performance Share Units"," "]
["Outstanding at beginning of period (in shares) | shares",{"v":285,"d":"285 "}]
["Granted (in shares) | shares",{"v":81,"d":"81 "}]
["Vested (in shares) | shares",{"v":-124,"d":"(124)"}]
["Adjustments for performance results (in shares) | shares",{"v":-3,"d":"(3)"}]
["Outstanding at end of period (in shares) | shares",{"v":239,"d":"239 "}]
["Weighted Average Grant-Date Fair Value Per Unit"," "]
["Outstanding at beginning of period (in dollars per share) | $ / shares",{"v":48.18,"d":"$ 48.18"}]
["Granted (in dollars per share) | $ / shares",84.67]
["Vested (in dollars per share) | $ / shares",38.12]
["Adjustments for performance results (in dollars per share) | $ / shares",38.12]
["Outstanding at end of period (in dollars per share) | $ / shares",{"v":65.8,"d":"$ 65.80"}]

{"sheet":"EARNINGS PER SHARE (Details)","index":52,"n_rows":19,"n_cols":3,"rows_kept":19,"merged":[[0,0,1,0],[0,1,0,2]]}
["EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Numerator:"," "," "]
["Net Income",{"v":122773,"d":"$ 122,773"},{"v":76884,"d":"$ 76,884"}]
["Basic"," "," "]
["Weighted average common shares outstanding (in shares)",{"v":63843,"d":"63,843 "},{"v":50045,"d":"50,045 "}]
["Diluted"," "," "]
["Stock options (in shares)",{"v":84,"d":"84 "},{"v":74,"d":"74 "}]
["Restricted stock units and awards (in shares)",{"v":215,"d":"215 "},{"v":99,"d":"99 "}]
["Contingent shares (in shares)",{"v":0,"d":"0 "},{"v":3,"d":"3 "}]
["Diluted weighted average common shares outstanding (in shares)",{"v":64142,"d":"64,142 "},{"v":50221,"d":"50,221 "}]
["Basic earnings per share (in dollars per share)",{"v":1.92,"d":"$ 1.92"},{"v":1.54,"d":"$ 1.54"}]
["Diluted earnings per share (in dollars per share)",{"v":1.91,"d":"$ 1.91"},{"v":1.53,"d":"$ 1.53"}]
["Share-based Payment Arrangement"," "," "]
["Dilutive Securities Included And Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"," "," "]
["Share based awards excluded from the calculation of diluted earnings per share (in shares)",{"v":44,"d":"44 "},{"v":40,"d":"40 "}]
["PSU"," "," "]
["Dilutive Securities Included And Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"," "," "]
["Share based awards excluded from the calculation of diluted earnings per share (in shares)",{"v":239,"d":"239 "},{"v":254,"d":"254 "}]

{"sheet":"SEGMENT DISCLOSURES - Additiona","index":53,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["SEGMENT DISCLOSURES - Additional Information (Details)","3 Months Ended"]
[null,"Mar. 31, 2025 segment"]
["Segment Reporting [Abstract]"," "]
["Number of business units of the company",{"v":3,"d":"3 "}]

{"sheet":"SEGMENT DISCLOSURES - Summary o","index":54,"n_rows":51,"n_cols":3,"rows_kept":51,"merged":[[0,0,1,0],[0,1,0,2]]}
["SEGMENT DISCLOSURES - Summary of Segment Information (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Segment Reporting Information [Line Items]"," "," "]
["Revenue",{"v":838014,"d":"$ 838,014"},{"v":494297,"d":"$ 494,297"}]
["Corporate & other:"," "," "]
["General & administrative expenses",{"v":28070,"d":"28,070 "},{"v":18711,"d":"18,711 "}]
["Interest expense",{"v":25156,"d":"25,156 "},{"v":4511,"d":"4,511 "}]
["Other (expense) income, net",{"v":1966,"d":"1,966 "},{"v":-9424,"d":"(9,424)"}]
["Income before income tax expense",{"v":172910,"d":"172,910 "},{"v":104014,"d":"104,014 "}]
["Operating Segments"," "," "]
["Segment Reporting Information [Line Items]"," "," "]
["Revenue",{"v":838014,"d":"838,014 "},{"v":494297,"d":"494,297 "}]
["Personnel costs",{"v":488122,"d":"488,122 "},{"v":293760,"d":"293,760 "}]
["Facility costs",{"v":26920,"d":"26,920 "},{"v":15580,"d":"15,580 "}]
["Other costs, gains, and losses, net",{"v":90562,"d":"90,562 "},{"v":51661,"d":"51,661 "}]
["Total segment expense",{"v":605604,"d":"605,604 "},{"v":361001,"d":"361,001 "}]
["Corporate & other:"," "," "]
["Income before income tax expense",{"v":232410,"d":"232,410 "},{"v":133296,"d":"133,296 "}]
["Operating Segments | Financial Services"," "," "]
["Segment Reporting Information [Line Items]"," "," "]
["Revenue",{"v":713661,"d":"713,661 "},{"v":372630,"d":"372,630 "}]
["Personnel costs",{"v":411302,"d":"411,302 "},{"v":216615,"d":"216,615 "}]
["Facility costs",{"v":23710,"d":"23,710 "},{"v":12335,"d":"12,335 "}]
["Other costs, gains, and losses, net",{"v":75296,"d":"75,296 "},{"v":36525,"d":"36,525 "}]
["Total segment expense",{"v":510308,"d":"510,308 "},{"v":265475,"d":"265,475 "}]
["Corporate & other:"," "," "]
["Income before income tax expense",{"v":203353,"d":"203,353 "},{"v":107155,"d":"107,155 "}]
["Operating Segments | Benefits and Insurance Services"," "," "]
["Segment Reporting Information [Line Items]"," "," "]
["Revenue",{"v":112976,"d":"112,976 "},{"v":108408,"d":"108,408 "}]
["Personnel costs",{"v":66665,"d":"66,665 "},{"v":65723,"d":"65,723 "}]
["Facility costs",{"v":3208,"d":"3,208 "},{"v":3182,"d":"3,182 "}]
["Other costs, gains, and losses, net",{"v":15158,"d":"15,158 "},{"v":14688,"d":"14,688 "}]
["Total segment expense",{"v":85031,"d":"85,031 "},{"v":83593,"d":"83,593 "}]
["Corporate & other:"," "," "]
["Income before income tax expense",{"v":27945,"d":"27,945 "},{"v":24815,"d":"24,815 "}]
["Operating Segments | National Practices"," "," "]
["Segment Reporting Information [Line Items]"," "," "]
["Revenue",{"v":11377,"d":"11,377 "},{"v":13259,"d":"13,259 "}]
["Personnel costs",{"v":10155,"d":"10,155 "},{"v":11422,"d":"11,422 "}]
["Facility costs",{"v":2,"d":"2 "},{"v":63,"d":"63 "}]
["Other costs, gains, and losses, net",{"v":108,"d":"108 "},{"v":448,"d":"448 "}]
["Total segment expense",{"v":10265,"d":"10,265 "},{"v":11933,"d":"11,933 "}]
["Corporate & other:"," "," "]
["Income before income tax expense",{"v":1112,"d":"1,112 "},{"v":1326,"d":"1,326 "}]
["Corporate And Eliminations"," "," "]
["Corporate & other:"," "," "]
["Unallocated corporate operating expenses",{"v":3797,"d":"3,797 "},{"v":15354,"d":"15,354 "}]
["General & administrative expenses",{"v":28070,"d":"28,070 "},{"v":18711,"d":"18,711 "}]
["Interest expense",{"v":25156,"d":"25,156 "},{"v":4511,"d":"4,511 "}]
["Other (expense) income, net",{"v":2477,"d":"$ 2,477"},{"v":-9294,"d":"$ (9,294)"}]

{"sheet":"SUBSEQUENT EVENTS (Details)","index":55,"n_rows":5,"n_cols":2,"rows_kept":5}
["SUBSEQUENT EVENTS (Details) - Interest Rate Swap, Effective April 2025 - Subsequent Event $ in Millions","Apr. 14, 2025 USD ($)"]
["Subsequent Event [Line Items]"," "]
["Derivative, term of contract","5 years"]
["Derivative, notional amount",{"v":50,"d":"$ 50"}]
["Interest rate swap, fixed interest rate",{"v":0.03503,"d":"3.503%"}]